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Abstract
Lung cancer is the leading cause of cancer related deaths world wide. The 
major cause of lung cancer is tobacco smoking. Tobacco smoke contains many 
different carcinogens including polycyclic aromatic hydrocarbons (PAH), which are 
known to cause DNA damage and initiate tumourigenesis. 
The aryl hydrocarbon receptor (AHR) is a basic helix-loop-helix protein of the 
PER-ARNT-SIM (PAS) family of transcription factors, which is involved in many bio-
logical processes including development, cell cycle regulation, cell differentiation, 
cell-cell signalling, cellular growth, and circadian rhythms. Most of the known func-
tion of AHR, however, is regarding its role in transcriptional induction of xenobiotic 
metabolising enzymes (XMEs). In the lung, PAHs bind and activate the AHR, lead-
ing to transcriptional induction of members of the cytochrome P450 (CYP) enzyme 
family that are involved in activation of pro-carcinogenic PAHs to carcinogenic me-
tabolites. 
MicroRNAs (miRNAs), a group of short non-coding RNA molecules, mediate 
sequence specific silencing of messenger RNAs (mRNAs) and are important in 
regulation of gene expression. The deregulation of certain miRNAs has been ob-
served in several types of cancer, including lung cancer. Like mRNAs, miRNAs be-
long to the class II type of genes, and transcription of these types of RNA can 
therefore be regulated by the same transcription factors.
Little is known regarding the role of miRNAs in environmental toxicology. The 
aim of this thesis was to identify miRNAs regulated by the AHR, and consequently 
may be important in mediating toxicity of tobacco smoke carcinogens. 
Expression levels of 750 miRNAs in mouse lung of Ahr wild-type and knock-
out animals were profiled by RT-qPCR arrays. Fifteen miRNAs were found to be 
differentially expressed between the groups, of which only one was up-regulated. 
The biological pathways in which these miRNAs may be involved were studied by 
an bioinformatic approach. Four miRNAs from the mouse experiment, whose ex-
pression were most significantly divergent, together with three miRNAs previously 
reported to be regulated by the Ahr in murine cell lines, were studied in an RNA 
interference (RNAi) experiment in immortalised human lung epithelial cell lines. Two 
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of these miRNAs, both selected from the literature, were found to have altered ex-
pression in AHR knockdown cells compared to control cells. Discrepancies be-
tween AHR regulated miRNAs identified in the in vivo and in vitro experiments were 
observed. Taken together this suggest a difference between effect of the AHR in 
vivo and in vitro, rather than differences between species.
In conclusion, it was found that expression of several miRNAs possibly is 
regulated in an AHR-dependent manner in lung. Discrepancies between in vivo and 
in vitro experiments suggest that care must be taken when extrapolating miRNA 
expression data from cell culture studies to whole organs or organisms.
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1. Introduction
1.1. Lung cancer
Cancer is the leading cause of 
death in the economically developed 
world, and the second leading cause of 
death in the economically developing 
world. In 2008, approximately 12.7 
million new cases of cancer were diag-
nosed, and 7.6 million cancer related 
deaths were recorded world wide. The 
rate of cancer is increasing in eco-
nomically developing countries as a 
result of population growth and ageing, 
as well as an increasing adaption of 
cancer associated lifestyle choices. 
This includes smoking, physical inactiv-
ity, and “westernised” diets1,2. 
Globally lung cancer is the sec-
ond most frequently diagnosed cancer 
and the leading cause of cancer death 
for females in both economically devel-
oped and developing countries, only 
bypassed by breast cancer. For males, 
lung cancer is the most frequently di-
agnosed cancer in developing coun-
tries, and the second most diagnosed 
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A B
Figure	  1.1:	  A)	   Incidence	   and	  mortality	  rates	  the	   20	  most	   common	  types	   of	  cancer	   in	  
male	  and	  female. 	  B)	  Incidence	  and	  mortality	  rates	  of	  lung	  cancer	  in	  males	  and	  females	  
in	  diﬀerent	  regions	  of	  the	  world2.
cancer in developed countries (Figure 
1.1).
Due to its strong association 
with tobacco smoking, lung cancer 
death rates are decreasing in most 
western countries, where tobacco epi-
demic peaked by the middle of the last 
century. In contrast, lung cancer rates 
are increasing in economically develop-
ing countries, for example in China and 
several other countries in Asia, and in 
several African countries. This is 
probably linked to increasing economi-
cal status enabling citizens to buy to-
bacco more recently in these countri-
es1. 
Lung cancer can be divided into 
two main types: Small cell lung cancer 
(SCLC) and non-small cell lung cancer 
(NSCLC). SCLCs are the most aggres-
sive forms of the disease and have a 
greater potential to metastasise than 
other type of lung cancer. NSCLCs are 
a group of different types of cancers, 
including squamous cell carcinoma 
(SCC), adenocarcinoma (ADC), and 
large-cell carcinoma (LCC) along with 
other minor subtypes3. Cigarette smok-
ing is significantly associated with all 
histological types of lung cancer4, in-
cluding adenocarcinoma, which also is 
the most common cancer type in never 
smokers3.
1.1.1. Risk factors
Tobacco smoking is strongly 
associated with lung cancer, and may 
also play a significant role in cancers of 
other sites like larynx, nasal cavity, oral 
cavity, oesophagus, liver, pancreas, 
cervix, bladder, and leukaemia5. To-
bacco smoking accounts for 80-90% 
of the worldwide lung cancer burden in 
males, and for at least 50% in fe-
males1. 
The strong association between 
lung cancer and cigarette smoking 
suggests that environmental carcino-
gens cause most cases of lung cancer. 
A carcinogen is any agent, chemical, 
physical, or viral, that causes cancer or 
increases the incidence of cancer. 
Cigarette smoke contains many differ-
ent carcinogens, the most important, 
based on carcinogenic potency and 
levels in smoke are considered 
polycyclic aromatic hydrocarbons 
(PAH), N-nitrosamines, aromatic 
amines, aldehydes, ethylene epoxides, 
1,3-butadiene, and benzene (Table 
1.1), of which the two last mentioned 
compounds are the most prevalent 
strong carcinogens5. N-nitrosamines 
are a large class of carcinogens that 
affect different tissues depending on 
their structure. The two most studied 
nitrosamines are 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK) and N’-
nitrosonornicotine (NNN), both only 
found in tobacco, and therefore termed 
tobacco specific nitrosamines (TSNA)5.
Risk of lung cancer is strongly 
associated with duration of smoking, 
and numbers of cigarettes smoked 
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also influence the relative 
risk. Smoking cessation is 
associated with reduction of 
relative risk of lung cancer 
among all smokers. This re-
duction in risk is observed 
within 1-4 years of cessation 
in both men and women, 
and the magnitude of the 
reduction in relative risk in-
creases with increased time 
since cessation4. 
Other risk factors for 
lung cancer include cooking 
fumes, radon, asbestos, ar-
senic, and PAHs from envi-
ronmental pollution1. An in-
creased risk of lung cancer 
has also been associated 
with certain occupations, 
such as transport workers, 
and in food processing and food serv-
ice occupations6. Exposure to indoor 
radon is estimated to be responsible 
for 9% of all lung cancer deaths in Eu-
rope3. 
Urban air particulate matter (PM) 
has been associated with increased 
risk of lung cancer7,8. PM is a complex 
mixture of airborne solid and liquid par-
ticles including soot, organic material, 
sulphates, nitrates, other salts, metals, 
and biological material. Carcinogenic 
compounds, such as PAH, are able to 
adsorb to the particles and may be 
deposited in the respiratory tract8. The 
combustion of fossil fuels is the source 
of most of the organic and inorganic 
compounds, oxidants, and acids, and 
contributes heavily to particulate air 
pollution in most urban settings9.
1.1.2. Genetic susceptibility 
to Lung Cancer
Even though there is a strong 
relationship between cigarette smoking 
and lung cancer, only 10-15% of all 
smokers develop lung cancer10. This, 
besides the cases of some non-
smokers developing lung cancer, sug-
gests that there might be differences in 
individual predisposition to lung cancer. 
There is also evidence for a 2-fold in-
13
Agent
Notable 
carcinogens
Amount in 
mainstream 
cigarette 
smoke 
Polycyclic aromatic 
hydrocarbons
Benzo[a]pyrene 8.5-11.6 ng
N-Nitrosamines NNK 110-133 ng
NNN 154-196 ng
Aromatic amines
4-Aminobiphenyl 2-5 ng
2-Naphthylamine 1-22 ng
Aldehydes
Formaldehyde 10.3-25 µg
Acetaldehyde 770-864 µg
Volatile 
hydrocarbons
1,3-butadiene 20-40 µg
Benzene 12-50 µg
Miscellaneous 
organic compounds
Ethylene oxide 7 µg
Vinyl chloride 11-15 µg
Table	  1.1:	  Some	   of	   the	  major	   groups	  of	  tobacco	  carcino-­‐
gens	  and	  the	  most	  importent	  within	  each	  group.	  Modiﬁed	  
from	  IARC	  Monograph	  83	  (2004)4
creased risk of lung cancer for indi-
viduals with a family history of lung 
cancer strongly indicating a heritable 
influence on susceptibility of lung can-
cer11. 
Predispositions in "hallmark of 
cancer" genes
Tumourigenesis is a multistep 
process characterised by accumulation 
of mutations resulting in defects in 
regulatory circuits that govern normal 
cell proliferation and homeostasis, and, 
ultimately, leads to invasive malignan-
cy12,13. In their transformation from 
normal to malignant state, cancer cells 
need to gain at least eight essential 
changes known as the “hallmarks of 
cancer”, first defined by Hanahan and 
Weinberg in 200013. The six essential 
alterations that cancer cells must gain 
are: Sustaining proliferative signals, 
evading growth suppressors, resisting 
cell death, enabling replicative immor-
tality, inducing angiogenesis, and acti-
vating tissue invasion and metastasis. 
Recently, the same authors added two 
new emerging hallmarks; deregulation 
of cellular energetics and avoiding im-
mune destruction. In addition, two 
enabling characteristics that drive tu-
mour progression were included: ge-
nome instability and mutation, and 
tumour-promoting inflammation (Figure 
1.2)14. 
The eight hallmarks of cancer 
each describe anticancer defence 
mechanisms that function to avoid and 
eliminate abnormalities, and 
cancer cells needs to prevail 
these safety mechanism to gain 
malignancy13. Inter-individual 
differences in susceptibility to 
cancer can be due to single nu-
cleotide polymorphisms (SNPs) 
in genes involved in any of these 
defence mechanisms, including 
DNA repair genes, telomerase 
genes, cell cycle regulating 
genes, or genes involved in 
inflammation15-17. 
For example, a mutation in epi-
dermal growth factor receptor 
(EGFR) has been associated with 
NSCLC, and mutations in the tumour 
suppressor gene TP53 in families with 
Introduction
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therapies. For example, the deployment of apoptosis-inducing
drugs may induce cancer cells to hyperactivate mitogenic
signaling, enabling them to compensate for the initial attrition
triggered by such treatments. Such considerations suggest
that drug development and the design of treatment protocols
will benefit from incorporating the concepts of functionally
discrete hallmark capabilities and of the multiple biochemical
pathways involved in supporting each of them. Thus, in partic-
ular, we can envisage that selective cotargeting of multiple
core and emerging hallmark capabilities and enabling character-
istics (Figure 6) in mechanism-guided combinations will result in
more effective and durable therapies for human cancer.
CONCLUSION AND FUTURE VISION
We have sought here to revisit, refine, and extend the concept of
cancer hallmarks, which has provided a useful conceptual
framework for understanding the complex biology of cancer.
The six acquired capabilities—the hallmarks of cancer—have
stood the test of time as being integral components of most
forms of cancer. Further refinement of these organizing princi-
ples will surely come in the foreseeable future, continuing the
remarkable conceptual progress of the last decade.
Looking ahead, we envision significant advances during the
coming decade in our understanding of invasion andmetastasis.
Similarly, the role of aerobic glycolysis in malignant growth will
be elucidated, including a resolution of whether this metabolic
reprogramming is a discrete capability separable from the core
hallmark of chronically sustained proliferation. We remain
perplexed as to whether immune surveillance is a barrier that
virtually all tumors must circumvent, or only an idiosyncrasy of
an especially immunogenic subset of them; this issue too will
be resolved in one way or another.
Yet other areas are currently in rapid flux. In recent years, elab-
orate molecular mechanisms controlling transcription through
chromatin modifications have been uncovered, and there are
Figure 6. Therapeutic Targeting of the Hallmarks of Cancer
Drugs that interfere with each of the acquired capabilities necessary for tumor growth and progression have been developed and are in clinical trials or in some
cases approved for clinical use in treating certain forms of human cancer. Additionally, the investigational drugs are being developed to target each of the
enabling characteristics and emerging hallmarks depicted in Figure 3, which also hold promise as cancer therapeutics. The drugs listed are but illustrative
examples; there is a deep pipeline of candidate drugs with different molecular targets and modes of action in development for most of these hallmarks.
668 Cell 144, March 4, 2011 ª2011 Elsevier Inc.
Figure	  1.2:	  Hallmarks	  of	  cancer.	  
Eight	   characterisIcs 	  that	  cells	  need	  to	  aJain	  
to	   become	   mutagenic,	   and	   two	  characteris-­‐
Ics	  that	   enable	   tumour	   cells 	  to	   grow.	   From	  
Hanahan	  &	  Weinberg	  (2011)14
Li-Fraumeni syndrome are associated 
with a slightly higher frequency of lung 
cancer and a lower age of occur-
rence15. The latter gene is activated by 
DNA damage, hypoxia, or aberrant 
oncogene expression and can subse-
quently promote DNA repair and apop-
tosis, and hence important in the de-
fence mechanism against cancer18. 
Polymorphism in inflammation associ-
ated genes may also play a role in can-
cer predisposition. For instance, a 
polymorphism in the pro-inflammatory 
genes interleukin-1 beta (IL1B) and 
COX2 has been associated with in-
creased risk of non-small cell lung can-
cer19,20.
Predisposition in xenobiotic 
metabolising and DNA repair genes
In relation to predisposition to 
lung cancer, SNPs in genes involved in 
metabolism of exogenous carcinogens 
are of importance. Metabolism of xe-
nobiotics is divided into three phases, 
each containing different types of xe-
nobiotic metabolising enzymes (XMEs) 
that metabolise, detoxifies, and excrete 
exogenous compounds. The first 
phase involves functionalisation, exe-
cuted by several different classes of 
enzymes, including mixed function oxi-
dase (cytochrome P450 or CYP), flavin 
monooxygenase, alcohol dehydroge-
nase, and epoxide hydrolase. Phase II 
XMEs are responsible for conjugation, 
either of compounds directly from the 
environment, or from metabolites of 
phase I enzymes. Important phase II 
metabolising enzymes are UDP-
glycosynyl transferase (UGT), sulpho-
transferase, and glutathione S-
transferase (GST). Phase III enzymes 
are responsible for further metabolism 
of phase II conjugates, such as me-
tabolism of glutathione conjugates by 
gamma-glutanyl-transpeptidase. Phase 
III enzymes are also responsible for the 
transport of the conjugates out of the 
cells and into bile or urine21. 
Polymorphisms resulting in al-
tered activity of any of the enzymes 
involved in xenobiotic metabolism can 
potentially lead to an increased risk of 
cancer, as a result of increased meta-
bolic activation, decreased conjuga-
tion, or decreased excretion22. For in-
stance, an association between early 
onset (age < 51) lung cancer in female 
and specific polymorphisms in cyto-
chrome P4501B1 (CYP1B1) and 
CYP2A13 has been shown23
Polymorphisms in DNA repair 
genes may cause interidividual differ-
ences in DNA repair capacity. Metabo-
lites of pro-carcinogens can bind DNA 
and form adducts, and if left unre-
paired, these adducts can cause muta-
tions that eventually may initiate tumour 
formation. An SNP in the DNA repair 
gene Xerodema Pigmentosum (XP) C, 
has been associated with a longer time 
to progression of NSCLC24
15
There is evidence of differences 
in lung cancer susceptibility between 
males and females, both in epidemiol-
ogical studies and in laboratory studi-
es25. Higher level of DNA-adducts have 
been found in females compared to 
that of males, both in vivo and in vi-
tro26,27. The higher DNA-adduct level in 
females may result from significantly 
higher levels of CYP1A1 and thus in-
creased bioactivation of certain to-
bacco carcinogens. One possible ex-
planation for this sex difference could 
be related to the AHR, but the authors 
did not find any differences in expres-
sion levels of AHR mRNA26. The differ-
ence in susceptability to lung cancer in 
male and female suggest that hormo-
nal factors may be involved in lung tu-
mourigenesis25,28.
1.1.3. Gene environment 
interactions
Only few cancers are caused by 
either environmental exposure or the 
individuals genetic make-up. Instead, 
the majority of cancers, including lung 
cancer, are caused by an interplay be-
tween environmental and genetic fac-
tors, so-called gene-environment inter-
actions. 
Gene-environment interactions 
can be divided into two categories: 1) 
diseases resulting from interactions 
between the individual genetic make-
up and environmental factors, 2) dis-
eases resulting from direct effects of 
environmental exposure on the ge-
nome, leading to for example DNA 
damage and/or mutations29. 
In any type of cancer, there are 
often significant differences in age of 
onset, rapidity of tumour growth, pres-
ence of metastases, pathological ap-
pearance, gene expression patterns, 
somatic genetic changes, response to 
therapy, and familial risk30. Identification 
of gene-environment interactions in 
tobacco-related cancers have proven 
to be complex due to several reasons, 
including the large number of genes 
involved in tobacco metabolism, the 
numerous substrates metabolised by 
relevant genes and the interaction of 
smoking with other metabolic path-
ways22.
1.2.The aryl hydrocarbon 
receptor
1.2.1.AHR basics
The AHR was first discovered in 
1976 by Poland et al. who discovered 
that tetrachlorodibenzo-p-dioxin (TCDD 
or simply dioxin) binds specifically to a 
receptor that induces expression of 
Cytochrome P450 1A1 (CYP1A1) and 
UDP-glucosynyl transferase in mouse 
liver31. The AHR can bind planar 
polycyclic ligands, for instance PAH 
and dioxins and dioxin-like compounds 
(DLC). The two most studied AHR 
ligands are the PAH benzo[a]pyrene 
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(B[a]P), and TCDD32. Also some dietary 
chemicals (for example flavonoids, ca-
rotenoids, and phenolics) can function 
as AHR ligands and activate transcrip-
tion of AHR targeted genes. However, 
these compounds seem to be relatively 
weak AHR ligands. Conversion of die-
tary indoles, including tryptophan, in 
the mammalian digestive tract to sig-
nificantly more potent AHR ligands has 
been demonstrated. There has also 
been an ongoing search for one or 
more endogenous AHR ligands, but no 
conclusions have been made. UV pho-
toproducts of tryptophan and histidine 
can directly bind to and activate 
AHR32,33. 
The AHR is a member of the 
basic helix-loop-helix/PER ARNT Sim 
(bHLH/PAS) family of transcriptional 
regulators, which have important roles 
in adaptive responses to generalised 
and cellular stress, besides playing key 
developmental roles. The bHLH motif is 
common to a wide range of transcrip-
tion factors all of which bind to DNA as 
dimers. bHLH/PAS proteins are sepa-
rated into two classes based on their 
17
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Figure	  1.3:	   Chemical	  structure	  of	  some	  known	  ligands	  of	  the	   aryl	  hydrocarbon	  receptor	  (AHR).	  
Benzo[a]pyrene	  and	  Dioxin	  is	  the	  two	  most	  extensively	  studied.	  
dimerisation potential. Class I factors 
are only capable of hetero-dimerisation 
with class II factors which, in contrast, 
are capable of both hetero- and homo-
dimerisation. Class I factors are located 
in the cytoplasm and functions as a 
sensory unit, that upon stimulation are 
translocated to the nucleus where they 
dimerise with class II factors, which 
resides in the nucleus. Upon dimerisa-
tion, the bHLH/PAS complex is able to 
bind DNA and activate transcription of 
target genes 34. The AHR, a bHLH/PAS 
class I protein, is the only vertebrate 
member of the bHLH/PAS family 
known to bind and be activated by 
small chemical ligands34.
1.2.2. Activation of AHR
In the unliganded, inactive state, 
the AHR is mainly located in the cyto-
plasm bound to a homodimer of the 90 
kDa heat shock protein (HSP90), one 
molecule of AHR interacting protein 
(AIP), and one HSP90 co-chaperon 
TP-23 (Figure 1.4). When a ligand as-
sociates with the AHR, a conforma-
tional change reveals a nuclear local-
isation signal in the AHR, which is rec-
ognised by importin-β. The entire AHR/
HSP90/AIP/TP-23 complex is translo-
cated to the nucleus, where the chap-
eron protein complex is exchanged by 
the AHR nuclear translocator (ARNT) 
protein35. After dimerisation, the AHR/
ARNT complex recognises and binds 
DNA at specific sequences in the pro-
moter region or in the enhancer of its 
target genes. The AHR/ARNT complex 
can recognise and bind to two different 
response elements, termed AH re-
sponse element I (AHRE-I, also called 
xenobiotic response element [XRE], or 
dioxin responsive element [DRE])36 and 
AHRE-II37. 
The activity of the exogenous 
ligand activated AHR can be inhibited 
by G-protein signalling pathways. 
Oesch-Bartlomowicz et al. (2005) 
found that when Hepa-1 cells were 
stimulated with cyclic-AMP (cAMP), 
AHR was activated and translocated to 
the nucleus. However, the cAMP-
activated AHR were not able to induce 
transcription of CYP1A1. Moreover, 
cAMP reduced the effect of TCDD-
activated AHR38. Nakata et al. (2009) 
found that G-proteins negatively regu-
lates AHR activity by competitively se-
questering AIP from the AHR complex. 
This leads to ubiquitination of AHR by 
an unknown E3 ubiquitin ligase, and 
ultimately results in translocation of 
AHR to the nucleus. As for the cAMP-
activated AHR, transcription of AHR/
ARNT target genes after exposure to 
3-MC was inhibited by G-protein acti-
vated AHR39. 
1.2.3. AHR in cellular 
processes
Originally AHR was studied as a 
pure xenobiotic metabolism activator. It 
has become evident, however, that the 
Introduction
18
AHR is involved in a vast range of bio-
logical processes, including develop-
ment, cell cycle regulation, cell signal-
ling, cytoskeleton organisation, extra 
cellular matrix (ECM) modification, ad-
hesion, immune responses, and cir-
cadian rhythm34,40-43. 
Although most of its known ac-
tions are dependent on ligand binding, 
the AHR seems to be able to activate 
some biological processes independ-
ent of an exogenous ligand. However, it 
is not known if endogenous ligands are 
involved in these processes since no 
such ligand has been identified44. Inter-
estingly, AHR in a transcriptionally ac-
tive form has been found to be local-
ised in the nucleus of cells in low con-
fluence culture, and as the confluence 
increases, AHR is translocated to the 
cytoplasm, a process associated with 
Ca2+ concentration45. This suggests a 
connection between cell-cell signalling 
mechanisms and AHR functions. 
Barhoover et al. (2010) showed 
that the AHR forms a complex with 
CDK4 and CCND1 in the absence of 
an exogenous ligand. This complex 
can phosphorylate RB1, leading to G1 
to S phase cell cycle transition. Expo-
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Figure	  1.4:	  Unliganded	  AHR	  is 	  located	  in	  the	   cytoplasm	  complexed	  with	  a	  HSP90	  dimer,	  AIP	  and	  
HSP90	  co-­‐chaperon	  p23.	  Upon	  ligand	  binding	  the	  complex	  translocates 	  to	  the	  nucleus,	  where	  the	  
chaperon	  proteins	  are	   exchanged	   for	  ARNT	   binding	   to	  AHR.	   The	   AHR/ARNT	   heterodimer	   then	  
binds	  response	  elements 	  (AHRE-­‐I	   	  or	  AHRE-­‐II)	   in	  promoters	  or	   enhancers	  of	  target	  genes	  and	  
induces	  transcripIon.	  Modiﬁed	  from	  Furness	  et	  al.	  (2007)32.	  
sure to an exogenous ligand will, how-
ever, result in dissociation of AHR from 
CDK4 and CCND1, resulting in de-
creased RB1 phosphorylation and G1 
cell cycle arrest46. Thus it seems that 
AHR may function as an environmental 
sensor that allows certain biological 
processes, such as cell cycle progres-
sion, only to occur in the absence of 
toxic compounds47.
In contrast to PAHs, TCDD is 
metabolically inert and hence does not 
lead to genotoxic metabolites. How-
ever, TCDD is known to be a potent 
tumour promoter, suggesting that tu-
mours are formed in another way than 
through DNA-adduct formation41. Tijet 
et al. (2006) showed that expression of 
456 genes was altered by TCDD in an 
AHR-dependent manner, while only 
expression of 32 genes were altered in 
an AHR-independent manner48. In ad-
dition they found that 392 genes were 
significantly differentially expressed be-
tween Ahr knockout (Ahr-/-) and 
wildtype (Ahr+/+) mice wihtout TCDD 
exposure. This demonstrates that 
most, if not all, of the tumourigenic ef-
fects of TCDD are mediated through 
AHR, and that carcinogenicity of AHR 
ligands is not solely mediated by direct 
DNA damage. 
1.2.4. Metabolism and 
carcinogenesis of PAH
One of the most extensively 
studied groups of carcinogens in 
relation to lung cancer are the PAHs. 
These compounds are products of in-
complete combustion and occur as 
mixtures in cigarette smoke, tars, 
soots, broiled foods, adsorbed to par-
ticulate matter, automobile engine ex-
haust (particularly diesel), and other 
materials generated by incomplete 
c o m b u s t i o n 5 . PA H s a r e p r o -
carcinogens that are activated to car-
cinogens by XMEs in the body. In 
phase I, PAHs are metabolised primar-
ily by CYP1A1 or CYP1B1, but in hu-
man lung CYP1A1 is the most impor-
tant enzyme in the bioactivation of 
B[a]P49. These activated, carcinogenic 
metabolites can form adducts with cel-
lular macromolecules and disrupt nor-
mal cell function if left unrepaired50.
The most widely studied PAH is 
benzo[a]pyrene (B[a]P). This PAH is not 
carcinogenic in itself, but in the body it 
is activated in a three step process to 
the carcinogenic metabolite (±)-
a n t i - 7β- 8α- d i h y d r o x y - 9α , 1 0α-
epoxy-7,8,9,10-tetrahydro-benzo[a]pyr
ene (BPDE), which can form DNA-
adducts at the N2 position of deoxy-
guanosine (BPDE-N2-dG). The first 
step in B[a]P metabolism is catalysed 
by CYP enzymes, forming (7R,8S)-
epoxy-7,8-dihydrobenzo[a]pyrene 
(B[a]P-oxide). This is converted to 
( 7 R , 8 R ) - d i h y d r o x y - 7 , 8 -
dihydrobenzo[a]pyrene (B[a]P-diol), 
catalysed by epoxide hydrolase. The 
last step is catalysed by CYP and other 
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enzymes, producing mainly BPDE 
(three other 7,8-diol-9,10-epoxide iso-
mers of B[a]P are also formed, but to a 
lesser extent than BPDE)51. 
Unrepaired DNA-adducts in tu-
mour suppressor genes or proto-
oncogenes and consequently muta-
tions in these genes may prompt tumo-
rigenesis. Adducts from B[a]P metabo-
lites mainly result in G→T or G→A mu-
tations, depending on the DNA se-
quence50. BPDE DNA-adducts have 
been observed in the TP53 tumour 
suppressor gene, which is mutated 
60% of all lung cancers52.The onco-
genic KRAS gene is mutated in ap-
proximately 30%-40% of adenocarci-
noma53. In Chinese women, there has 
been found an association between the 
use of smokey cole for heating and 
cooking, and risk of lung cancer. The 
emissions from the coal consist of 43% 
PAH. In lung tumours studied by De-
Marini et al., the KRAS gene was found 
to be mutated in 29% of the cases, 
with mainly G→T transversions54.
1.3.Epigenetics in 
Cancer
Epigenetics is defined as so-
matically heritable changes in gene 
expression that are not a consequence 
of changes in the DNA sequence. Epi-
genetics comprise a number of 
mechanisms, including DNA methyla-
t ion, h is tone modificat ion, and 
microRNAs (miRNAs). Animal studies 
indicates that prenatal and early post-
natal environmental factors, including 
nutritional supplements, xenobiotic 
chemicals, behavioural cues, reproduc-
tive factors, and low-dose radiation, 
can result in altered epigenetic pro-
gramming and subsequent changes in 
the risk of developing disease55. Epige-
netic changes can be inherited mitoti-
cally in somatic cells, which indicates 
that environmental effects on the epi-
genome can result in long-term effects 
on gene expression55.
 To better understand gene-
environment interactions, epigenetics 
should be added to classic genetic 
analysis. Changes in DNA methylation 
pattern, chromatin structure, or miRNA 
expression. Polymorphism in miRNAs 
or in miRNA-targeted sequences in 
3’UTR of mRNAs, may also result in 
phenotypic changes. For example, 
polymorphisms in the 3’UTR of ATP 
binding cassette (ABC) B1 and ABCC1 
which may alter miRNA binding, have 
been associated with an increased risk 
of lung cance56. 
As mentioned previously, gene-
environment interactions can be di-
vided into two groups (see section 1.2). 
In the same way, epigenetic effect can 
be divided into two similar groups: 1) 
diseases resulting from epigenetic dif-
ferences making individuals less or 
more vulnerable to environmental in-
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sults, 2) diseases resulting from altera-
tion of epigenetic states caused by 
environmental exposure, for example 
changes in histone modification, DNA 
methylation, or miRNA expression29. 
Epigenetic alterations might be inher-
ited transgenerationally, thereby poten-
tially affecting the health of future gen-
erations. However, although epigenetic 
states of some genomic regions have 
proven to be inherited across genera-
tions in animal models, no such inheri-
tance has so far been proven in hu-
mans29,55.
DNA methylation
DNA methylation is a covalent 
modification, heritable by somatic cells 
after cell division, and is important in 
regulating many cellular processes, 
including chromatin structure, X-
chromosome inactivation, genomic 
imprinting, chromosome stability, and 
gene transcription57. DNA can be 
methylated at the 5-position of a cyto-
sine ring in a CpG dinucleotide. CpG 
sites are asymmetrically distributed into 
CpG poor regions and CpG dense re-
gions called CpG islands. These CpG 
islands are often located in the pro-
moter region of protein coding genes, 
and their methylation is associated with 
gene silencing. Aberrant DNA methyla-
tion of tumor suppressor genes occurs 
in many types of cancer. 
DNA methylation is carried out 
by DNA methylatransferases (DNMTs). 
There are three major DNMTs with 
different specific tasks; DNMT3A and 
3B are responsible for de novo methy-
lation, while DNMT1 is responsible for 
maintaining already existing methylation 
patterns58. In cancer cells, CpG islands 
that are normally unmethylated may 
become methylated, or conversely, 
some genes that are normally methy-
lated may become unmethylated, re-
sulting in activation of normally silenced 
genes, such as oncogenes or retro-
transposons59. 
Histone modification
DNA is packed into chromatin, a 
dynamic structure consisting of 146 
base pairs (bp) of DNA wrapped 
around nucleosome protein com-
plexes. The nucleosome is composed 
of an octamer of four core histones, an 
H3/H4 tetramer and two H2A/H2B 
dimers59. Histones can be modified by 
addition of chemical groups to their 
tails. Types of modification include ace-
tylation, methylation, phosphorylation, 
sumoylation, and ADP ribosylation, 
resulting in opening or condensing of 
the chromatine structure. 
The most common modifications 
are acetylation and methylation of ly-
sine residues in the amino terminal of 
histone 3 (H3) and histone 4 (H4). In-
creased acetylation induces transcrip-
tion activation, whereas decreased 
acetylation usually induces transcrip-
tion repression. Methylation of histones 
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is associated with repression or activa-
tion of transcription, depending on the 
lysine residue position29. Besides 
modification of histones, nucleosomes 
can be modified by incorporation of 
different histone variants. For instance, 
the histone variant macroH2A have 
been shown to be involved in regula-
tion of HOXA gene cluster in zebrafish 
development, and in X-chromosome 
inactivation in females60.
RNA interference
 RNA interference (RNAi) con-
ducted by double-stranded (ds)RNA 
molecules was first described in 1998 
by Fire and co-workers61, who discov-
ered that injection of short dsRNA (20-
30 nucleotide [nt]) into Caenorhabtidis 
elegans resulted in phenotypes similar 
to that expected in knock out animals. 
They found that these phenotypes re-
sulted from specific knock down of 
mRNAs containing sequences compli-
mentary to the injected siRNA. For their 
discovery, Andrew Fire and Craig Mello 
were awarded the Nobel Prize in 
Physiology or Medicine in 2006, less 
than ten years after their original dis-
covery. 
The effects of small RNAs on 
gene expression are generally inhibi-
tory, and the corresponding regulatory 
mechanisms are therefore collectively 
termed RNA silencing. The central 
theme is that the small RNAs serve as 
specificity factors that direct associated 
effector proteins to target nucleic acid 
molecules via base-pairing interactions. 
Invariably, the core component of the 
effector machinery is a member of the 
Argonaute protein superfamily. Small 
RNAs are grouped into three main 
categories; short interfering RNAs 
(siRNA), microRNAs (miRNA), and piwi-
interacting RNAs (piRNA), based on 
their origins, structures, associated 
effector proteins, and biological roles62.
1.4. miRNA
The first discovery of small RNA 
molecules involved in the cells innate 
mechanism for regulation of gene ex-
pression came in 1993 when Ambros, 
Feinbaum, and Lee found an RNA-
molecule coded by the lin-4 gene to be 
important in regulation of the lin-14 
mRNA in C. elegans. However, the 
mechanism for which these short, non-
coding RNA molecules lead to gene 
repression was not understood until 
Fire and Mello's discovery in 1998. 
Ambros and co-workers identi-
fied two RNA molecules of different 
length, one consisting of 61 nucleo-
tides (nt), the other of 22 nt. The long-
est was predicted to have a stem-loop 
structure in which the lin-14 antisense 
sequence was located within the stem, 
probably leaving it unable to base-pair 
with the mRNA. They also found sev-
eral repeated sequences in the 3’ un-
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translated region (3’UTR) of lin-14 
mRNA that were complementary to the 
5’ end of the shortest lin-4 RNA, sug-
gesting post-transcriptional regulation 
of gene expression by antisense RNA 
binding63. It took seven years from this 
discovery to the identification of the 
second microRNA, named let-7, in year 
200064. Today, 1048 microRNAs have 
been identified in human and 720 in 
mouse (Mus musculus) (miRBase re-
l e a s e 1 6 , S e p t e m b e r 2 0 1 0 , 
http://www.mirbase.org)65.
1.4.1.Transcription of miRNA 
genes
miRNA genes are located 
throughout the genome in either inter-
genic regions or in introns of protein 
coding genes. miRNAs located in in-
trons of protein coding genes can be 
transcribed together with the mRNA, 
and may thus underlie the transcrip-
tional regulation of the corresponding 
mRNA, or, less common, they can be 
transcribed by intron-resident promot-
ers independent of host gene promot-
ers66. miRNA genes located in inter-
genic regions are transcribed from their 
own transcription start site (TSS) and 
are transcriptionally regulated by their 
own promoter regions. These miRNAs 
are transcribed into primary precursor 
miRNAs (pri-miRNA) that are more than 
one kilo base-pair in length. Some 
miRNA genes are located in clusters of 
2-7 miRNA genes separated only by a 
few base-pairs67. These miRNAs are 
transcriptionally regulated by a single 
promoter, and thus transcribed to-
gether as a single, polycistronic pri-
miRNA molecule.
The primary transcripts are 
processed into mature miRNAs in two 
sequential processing steps, the first 
taking place in the nucleus and the 
second in the cytoplasm68. miRNA 
genes are transcribed as capped and 
polyadenylated69 transcripts of more 
than 1 kb in length by RNA polymerase 
II70. Most, if not all, miRNA genes con-
tain the same type of promoters as 
protein coding genes71, raising the 
possibility that microRNA genes can be 
regulated by the same type of tran-
scription factors as mRNAs, such as 
enhancers or hormones72,73. To under-
stand how miRNAs are involved in 
regulating different biological pathways, 
understanding how miRNAs them-
selves are regulated is important. In-
vestigating effects of known transcrip-
tion factor’s on the expression of 
miRNAs can provide key information of 
the complexity of miRNA conducted 
post-transcriptional regulation. 
1.4.2.Maturation of miRNA
Primary miRNA transcripts, pri-
miRNAs, are processed into mature 
microRNAs in two separate steps, both 
catalysed by RNase III enzymes in 
complex with dsRNA-binding proteins 
(Figure 1.5). The first step occurs in the 
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nucleus, where the pri-miRNA is 
cleaved by the RNase III enzyme Dro-
sha and its partner DiGeorge syndrome 
critical region gene 8 (DGCR8), creat-
ing a ~70 nt long precursor microRNA 
(pre-miRNA)74,75. Some spliced out 
mRNA introns in C. elegans, Droso-
phila melanogaster, and mammals cor-
responds precisely to pre-miRNAs. 
These “mirtrons” circumvent the need 
for Drosha-DGCR8 complex75. 
The pre-miRNA is exported to 
the cytoplasm by Exportin-5 (XPO5)76. 
In the cytoplasm the pre-miRNA is fur-
ther processed into a ~22 nt long du-
plex (miRNA:miRNA*) by the RNase III 
enzyme Dicer in complex with TAR 
RNA binding protein (TRBP)77,78. This 
step can also occur independently of 
Dicer, but although found throughout 
the animal kingdom, this is less com-
mon79,62. One of the strands in this 
duplex is incorporated into the RNA 
induced silencing complex (RISC), 
forming miRISC, and guides sequence 
specific nuclease activity resulting in 
degradation of mRNAs, or translational 
inhibition of mRNAs containing se-
quences complementary to the miRNA 
in their 3’ untranslated region80 
(3’UTR).
1.4.3.RISC mediated 
transcriptional regulation
The mature miRNA is loaded 
into the Argonaut (AGO) effector pro-
tein of the RISC assembly. Only one of 
the strands, the guide strand, directs 
the silencing complex to mRNAs con-
taining complementary sequences by 
Watson-Crick base pairing62. Generally, 
the strand with the 5’ terminus located 
at the thermodynamically less stable 
end of the miRNA:miRNA* duplex is 
selected to function as the mature 
miRNA, and the other strand is de-
graded75. 
The RISC executes post-
transcriptional silencing either by se-
quence specific degradation of mRNA 
target, or by repression of translation. If 
there is complete complementarity be-
tween the guiding small, non-coding 
RNA molecule and the targeted mRNA, 
AGO slices the message at the position 
opposite the phosphate between the 
tenth and the ninth base from the 5’ 
end of the guide. This slicing mecha-
nism is the pathway most often used 
by short interfering RNAs (siRNAs) that 
is utilised in gene-knockdown technol-
ogy. 
In the case of microRNAs, how-
ever, there is not full complementarity 
between the guide strand and the tar-
get strand. The 5’-region has been 
shown to be the most evolutionary 
conserved part of the miRNA, suggest-
ing that this region is important in me-
diating the effect of miRNAs. Indeed, 
nucleotide 2-8 in the 5’-region of the 
miRNA has been identified as the most 
important in prediction of mRNA tar-
gets, and these nucleotide region have 
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therefore been named the “seed” re-
gion81. In the cases where the guiding 
RNA is not fully complementary with 
the target, RISC binds and sequesters 
the transcripts away from the transla-
tional machinery into cytoplasmic foci 
termed P-bodies82.
Although miRNAs may decrease 
protein output by direct inhibition of 
translation, Guo et al. (2010) showed 
that at least 84% of the effect of 
miRNAs is due to reduction in mRNA 
levels83. The exact mechanism of 
translational repression is not com-
pletely known, but it most likely in-
vo lves miRNA mediated mRNA 
deadenylation, which is the initiation 
step of mRNA catabolism82,75.
1.4.4. Biological impact of 
miRNAs
Mammalian miRNAs are pre-
dicted to control the expression of 
more than 60% of all protein coding 
genes84. MicroRNAs seem to have a 
modest effect of less than 30% down-
regulation on most of its targets, al-
though some mRNAs can be down-
regulated 50%-80%85. However, this 
does not mean that modest down-
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Figure	   1.5:	   MicroRNAs	   are	   maturated	   in	   two	   steps 	   executed	   by	   diﬀerent	   RNase	   III	   family	  
enzymes.	   The	   mature	   miRNA:miRNA*	   duplex	   is 	  loaded	   into	   the	   RISC,	   where	   only	   one	   of	   the	  
strands	  is	  used	  to	  guide	  silencing	  of	  target	  mRNAs.	  The	  other	  strand	  is 	  discarded.	  Modiﬁed	  from	  
Filipowicz	  et	  al.	  (2008)72.
regulation of the targets is out of bio-
logical importance. On the contrary the 
miRNA may be evolutionary conserved 
due to its effect on dampening and fine 
tuning, rather than switching off, its 
target messages. Moreover, since each 
miRNA can target several mRNAs, and 
conversely, each mRNA can be tar-
geted by several miRNAs, the cumula-
tive effect miRNA mediated suppres-
sion could be of biological significance, 
even when the effect of the single 
miRNA is modest86. 
Bartel (2009) has suggested a 
model of three types of miRNA medi-
ated expression regulation (Figure 1.6). 
First, miRNA can function in a classical 
switch, down regulating expression of 
its target genes to an inconsequent 
level. This type of regulation occurs for 
example as to repress aberrant ex-
pression of certain genes in certain 
tissues. Second, as already mentioned, 
miRNAs may act as to tune, rather 
than as a binary switch, to dampen 
protein output to a more optimal level 
but one that is still functional. Third, 
neutral interactions may dampen pro-
tein output, but this repression is toler-
ated or offset by feedback mecha-
nisms such that the regulatory sites are 
under no selective pressure to be re-
tained or lost during evolution. Neutral 
interactions comprise cases in which 
biological targeting has no biological 
function87.
Even with a down-regulating 
effect of 30%, miRNAs can have a big 
impact on mRNA half-life, resulting in a 
rapid decrease of mRNA87. This is of 
biological importance because it 
makes cel ls amenable to quick 
changes, for instance in response to 
environmental changes. 
1.4.5. miRNA in cancer
Since miRNAs are believed to be 
involved in almost all biological proc-
esses, it is also likely that they are also 
involved in diseases such as cancer. 
The expression of many genes have 
been shown to differ between individu-
als, and these differences in expression 
levels have been found to have an in-
herited component. Since miRNAs tar-
gets a number of functionally important 
protein coding genes, variations in the 
expression and/or sequence of 
miRNAs inherited in the germ-line, 
could be important in cancer predispo-
sition by affecting the expression levels 
of tumour-suppressor genes or onco-
genes88. 
The expression level of miRNAs 
is found to be globally down regulated 
in tumour cells, and this has been as-
sociated with formation of more ag-
gressive tumours in animals, suggest-
ing that overall loss of miRNA expres-
sion enhances tumourigenesis. This 
global down regulation may function as 
to repress the expression of miRNAs 
functioning as tumour suppressors89. 
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A few miRNAs have been shown 
to be up regulated in tumour cells, 
functioning as oncogenes or “on-
comirs”. For example, Martello et al. 
(2010) showed that miR-103/107 ex-
pression is induced in breast cancer 
cells. These miRNAs targets and down 
regulate Dicer, thus lowering the rate of 
miRNA maturation. Silencing of miR-
103/107 inhibited metastasis, suggest-
ing that a lower miRNA level is neces-
sary for tumour cells to gain metastatic 
potential90. In addition, down regulation 
of Dicer is associated with poor prog-
nostic impact on survival rate in lung 
cancer91. 
	 Another example of on-
comirs is the mir-17~92 cluster, which 
consists of six miRNAs. This cluster is 
located in a chromosomal region that is 
frequently amplified in a subset of hu-
man B cell lymphomas, and over-
expressed in a variety of human 
cancers92.
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(Figure 5A). In this scenario, the miRNA sets a more stringent 
threshold for consequential transcriptional activity, which can 
help quiet stochastic cell-to-cell noise during developmental 
fate decisions (Cohen et al., 2006). For example, targeting of 
senseless by miR-9a in !y epithelial cells prevents sporadic 
production of extra neuronal precursor cells (Li et al., 2006). 
At their extreme, such switch interactions can be regarded as 
failsafe interactions. For both classical switch interactions and 
failsafe interactions, the miRNA represses protein output to 
inconsequential levels, but failsafe interactions differ because 
protein output falls below functional levels even in the absence 
of the miRNA. For failsafe interactions, miRNA repression adds 
an additional, functionally redundant layer of repression, help-
ing to ensure that aberrant transcripts do not give rise to a 
consequential amount of protein. Proposed examples of fail-
safe targeting include the miR-1 repression of nonmuscle Tro-
pomyosin isoforms and nonmuscle V-ATPase subunits in the 
developing muscle (Stark et al., 2005).
Tuning interactions are those for which the miRNA acts as 
a rheostat rather than a binary off-switch to dampen protein 
output to a more optimal level but one that is still functional in 
the cell (Figure 5A), thereby enabling more customized expres-
sion in different cell types as well as more uniform expression 
within each cell type. A recent example is the Drosophila miR-8 
regulation of atrophin, which reduces protein output to a level 
that prevents neurodegeneration but not so low as to compro-
mise viability (Karres et al., 2007). Another likely example is the 
miR-375 targeting of Myotrophin (Mtpn), which dampens Mtpn 
output in pancreatic islets to a more optimal level but one that 
remains functional for insulin secretion (Poy et al., 2004). In the 
case of Mtpn targeting, the miRNA level remains constant in 
the adult animal, illustrating that the regulation need not be 
dynamic to be classi"ed as tuning.
Neutral interactions dampen protein output, but this repres-
sion is tolerated or offset by feedback mechanisms such that 
the regulatory sites are under no selective pressure to be 
retained or lost during the course of evolution (Figure 5A). Neu-
tral interactions comprise cases in which biological targeting 
(i.e., targeting occurring in the animal) has no biological func-
tion. Because 7–8 nt sites so frequently fall in contexts suit-
able for repression in the animal, many “bystander” messages 
that fortuitously pair to coexpressed miRNAs are likely subject 
to neutral repression. Indeed, when endogenous miRNAs are 
inhibited or removed, most derepressed messages have non-
conserved sites (Krutzfeldt et al., 2005; Giraldez et al., 2006; 
Rodriguez et al., 2007; Baek et al., 2008), raising the possi-
bility that neutral repression might be the most frequent type 
of biological repression. However, this possibility is dif"cult to 
con"rm because tuning or switch interactions can have useful 
lineage-speci"c functions, and antitargets can have detrimen-
tal sites that have yet to be lost.
Comparing the expression of the miRNAs with that of their 
predicted targets can provide important clues to the more 
prevalent regulatory effects of metazoan miRNAs. In Droso-
phila, expression of miRNAs and their conserved targets usu-
ally appears to be “mutually exclusive,” as judged by in situ 
hybridization (Stark et al., 2005). Microarray data from mam-
mals paint a similar picture of a mutually exclusive tendency 
when considering messages with nonconserved sites (dis-
cussed above). However, the array data, which have greater 
dynamic range than do in situ hybridization data, suggest a 
different picture for messages with conserved sites, indicat-
ing that although the conserved mRNA targets tend to be 
expressed higher in tissues that lack the miRNA, they are still 
usually detected, albeit at lower levels, in tissues that express 
the miRNA (Farh et al., 2005; Sood et al., 2006). When miRNA-
expressing cells are puri"ed to cellular resolution, this ten-
dency for some overlap between miRNA and target expres-
Figure 5. MicroRNA-Mediated Regulatory Effects
(A) Classes of miRNA regulatory interactions (Bartel and Chen, 2004). Left 
panels: in response to a developmental or env onmental cue, cells induc  
miRNA expression (blue), which in turn dampens protein production (purple) 
from the targeted message. Right panels: protein production from analogous 
targ ts also can be dampened by pre-existing miRNAs; accumulation in the 
absence of the miRNA is indicated (dashed line). All panels depict 33% re-
pression, which illustrates that classi"cation does not rely on the magnitude 
of repression but instead depends on the properties of each target, namely 
its threshold(s) for optimal protein output. These thresholds are depicted as 
the boundaries between the clear (optimal) and colored (suboptimal) regions 
of the graphs.
(B) Modest destabilization transitions to much greater repression after the 
mRNA is no longer transcribed. A miRNA is induced (point a) and mediates 
modest (2-fold) mRNA destabilization. After transcription of the mRNA halts 
(point b), the same modest destabilization quickly yields substantial (t10-fold) 
repression of protein output. If the miRNA also mediates translational repres-
sion (not considered in this example), the transition to the off state is acceler-
ated further.
Figur	  1.6:	   Lec	  panels:	   in	  response	  to	  a	  developmental	  or	  environmental	  cue,	  cells	  induce	  miRNA	  
expression	  (blue),	   which	   in	   turn	  dampens	  protein	  producIon	  (purple)	   from	   the	   targeted	  mes-­‐
sage.	  Right	   panels:	   protein	  producIon	  from	   analogous	  targets	  also	   can	  be	   dampened	  by	  pre-­‐
exisIng	  miRNAs;	  accumulaIon	  in	  the	  absence	  of	  the	  miRNA	  is	  indicated	  (dashed	  line).	  All	  panels	  
depict	  33%	   re-­‐	  pression,	   which	  illustrates 	  that	  classifcaIon	  does	  not	   rely	  on	  the	  magnitude	   of	  
repression	  but	   instead	  depends	  on	  the	  properIes	  of	  each	  target,	  namely	  its	  threshold(s)	  for	  op-­‐
Imal	  protein	  output.	  These	  thresholds	  are	  depicted	  as	  the	  boundaries 	  between	  the	   clear	   (opI-­‐
mal)	  and	  colored	  (subopImal)	  regions	  of	  the	  graphs.	  From	  Bartel	  (2009)84.
	 miRNAs may be used as 
diagnostic markers for early detection 
of certain cancer types. In addition, 
miRNA expression patterns may be a 
valuable tool in distinguishing histologi-
cal types of cancer. For example, dif-
ferent miRNA expression patterns have 
been identified, that may be used to 
distinguish small cell lung cancer from 
normal human bronchial epithelial cells 
and from non-small cell lung cancer93.
miRNA and the environment
miRNA transcription seems to 
be tightly regulated in a temporal or 
tissue-specific manner, and an interest-
ing question is if this regulation can be 
modulated by environmental factors. 
The role of miRNAs in complex net-
works in the field of toxicology is cur-
rently largely unknown84. Nevertheless, 
an emerging number of studies are 
indicating connections between envi-
ronmental exposure, aberrant miRNA 
expression, and tumour formation. 
In a global miRNA expression 
analysis of healthy current smokers and 
never smokers, many miRNAs were 
found to be down-regulated and their 
respective mRNA targets were found to 
be up-regu lated94. Th is down-
regulation of miRNAs is interesting 
when compared to the global down-
regulation of miRNAs in cancerous tis-
sue, because it indicates that aberrant 
miRNA expression might be detected, 
because of exposure, in healthy tissue 
before tumour formation.    This finding 
suggests that aberrant miRNA expres-
sion may be an underlying factor in 
disease initiation84. 
Izzoti et al. (2009) found 126 
miRNAs to be down regulated more 
than a twofold, and only one miRNA to 
be dramatically up-regulated, in lung in 
response to exposure of environmental 
cigarette smoke (ECS). The up-
regulated miRNA, miR-294, causes 
silencing of some transcriptional re-
pressors, thereby resulting in a global 
increase of gene transcription as re-
sponse to ECS95. Exposure to dioxin 
was found to result in small changes of 
miRNA expression in liver, and the 
authors suggested that hepatic 
miRNAs are refractory to dioxin96. 
However, the biological effect of small 
changes in miRNA levels can be of 
significant magnitude due to the num-
ber of potential targets regulated by 
individual miRNAs97. 
1.5. Aim of study
Little is known about the role of 
the AHR in regulation of miRNA ex-
pression. AHR is a ligand activated 
transcription factor involved in xenobi-
otic metabolism, and hence important 
in mediating cellular response to envi-
ronmental pro-carcinogens. miRNAs 
are predicted to be involved in most, if 
not all, biological processes in the cell, 
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and may play an important role in this 
response as negative regulators of 
gene expression of specific target 
genes. miRNAs are known to be de-
regulated in several types of cancer, 
including cancers of the lung, and 
knowledge of how miRNA expression 
is controlled can elucidate their role in 
tumourigenesis.
The aim of this thesis was to identify 
the effect of the AHR on miRNA 
expression. Specifically we wanted to: 
• Identify differentially expressed 
miRNAs in lung of Ahr KO and wild 
type mice
• Study if expression of these also is 
controlled by the AHR in human lung 
epithelial cells in vitro
• Verify if known Ahr regulated miRNAs 
in mur ine ce l l s show s imi la r 
regulation in human lung epithelial 
cells in vitro.
• Explore if miRNAs are subjected to 
regulation by exposure to chemical 
carcinogens (B[a]P and CSC) in 
human lung epithelial cells in vitro
To identify miRNAs regulated by 
AHR, an Ahr knockout mice experi-
ment was carried out. Expression lev-
els of 750 miRNAs were measured by 
RT-qPCR array and miRNAs differen-
tially expressed between Ahr-/- and 
Ahr+/+ mice were identified by statistical 
testing. Bioinformatic analysis was per-
formed to identify predicted targets of 
the differentially expressed miRNAs. 
Expression of four selected differentially 
expressed miRNAs from the mouse 
experiment, together with three 
miRNAs previously reported to be dif-
ferentially expressed in an AHR de-
pendent manner, were further analysed 
in a RNA interference experiment in 
human bronchial epithel ial cel ls 
(HBEC3-KT) in vitro.
Introduction
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2. Methods
List of all materials used in the experi-
ments are provided in Appendix A. Fig-
ure 2.1 shows the work flow for the 
experiments performed for this thesis. 
2.1.AHR KO Mice 
Experiment
For analysis of the effect of aryl 
hydrocarbon receptor (Ahr) on miRNA 
in mouse lung, expression profiling was 
performed on an Ahr knockout mouse 
model. The Ahr heterozygote model 
(C57BL6) was interbred to generate 
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Figure	  2.1:	  Flow	  chart	  describing	  the	  work	  ﬂow	  for	  idenIﬁcaIon	  of	  AHR	  regulated	  miRNAs	  in	  
vivo	  and	  in	  vitro.	  
Ahr+/+ (wild-type) and Ahr-/- (knockout) 
mice. Genotyping was performed as 
described in98. The mice were main-
tained at the animal department at 
STAMI in a germ-free facility using an 
air-filtered controlled environment. The 
animals were fed a standard diet (B&K 
Universal A/S, Norway) and provided 
water ad libitum. 
The mice used in this study were 
part of the study described in98, were 
the effect of B[a]P on adduct formation 
in Ahr-/- mice was investigated. The 
mice were exposed to B[a]P solubilised 
in corn oil (10 mg/mL), while the control 
group were given pure corn oil (vehi-
cle). In this thesis only the control ani-
mals were used. The study consisted 
of six Ahr-/- mice (three male and three 
female) and six Ahr+/+ mice (three male 
and three female, total of 12 mice). The 
experiment was conducted according 
to the standards for care and use of 
experimental animals, and was ap-
proved by the Norwegian Reference 
Centre for Laboratory Animal Science 
and Alternatives. 
Twenty-four hours after oral 
dose of corn oil the animals were sacri-
ficed. The lungs (as well as other or-
gans such as liver, spleen, kidney, and 
heart) were harvested, snap frozen in 
liquid nitrogen, and stored at -80°C. 
2.2.Effect of AHR on 
microRNA expression in 
vitro
To validate results from the Ahr 
knockout mice experiments, expres-
sion levels were investigated in vitro for 
the selected miRNAs along with three 
miRNAs chosen based on their previ-
ously reported AHR dependent regula-
tion. These were miR-494, reported to 
be induced following B[a]P exposure in 
primary murine bronchial epithelial cells 
in vitro99; miR-122a has been reported 
to be induced by TCDD exposure in 
Hepa-1 mouse cells in vitro; and miR-
203, reported to have increased ex-
pression in Hepa-1 rat cells in vitro af-
ter TCDD exposure96.
miRNA expression levels were 
investigated in vitro in immortalised 
human bronchial epithelial cell line 
(HBEC3-KT). This cell line is estab-
lished from a 65 year old female 
smoker with no cancer, immortalised 
by overexpressing two genes associ-
ated with growth arrest. Telomerase 
reverse transcriptase (TERT) is over-
expressed to prevent telomere shorten-
ing and bypass telomere-dependent 
senescence, and cyclin dependent 
kinase 4 (CDK4) is overexpressed to 
bypass premature growth arrest medi-
ated by CDK inhibitor p16INK4a100. 
Three independent experiments 
were conducted, each containing two 
replicates of each sample and control. 
Materials and method
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Samples were transfected with AHR 
short-interfering RNA (siRNA) in order 
to knock down AHR gene function. 
Control cells were transfected with two 
control siRNA molecules with different 
GC level. These controls are of the 
same length as the gene specific siR-
NAs, but they do not have any known 
targets in the human genome. Cells 
were subsequently exposed to B[a]P, 
CSC or dimethyl sulfoxid (DMSO, vehi-
cle) for one day or 5 days. Total RNA 
was isolated using TRIzol-RNA lysis 
reagent, and qScript (Quanta) and 
miScript (Qiagen) was used for RT-
qPCR analysis of mRNA and mi-
croRNA, respectively (see sections be-
low). 
2.3.Cell culture
See appendix B for information 
on general cell culture work. 
Human bronchial epithelial cells 
were taken from STAMIs cell bank, 
were they were stored in liquid nitro-
gen. All cells were cultured in LHC-9 
medium (Invitrogen) added 1% penicil-
lin and streptomycin, unless stated 
otherwise. All cells were grown on col-
lagen coated dishes (see appendix 
B.3). Incubation conditions were 37°C 
and 5% CO2. All cell culture work was 
performed under sterile conditions in 
OAS LAF benches. 
2.3.1. Seeding of cells for 
experiment
Cells seeded for transfection 
experiment were cultured in LHC-9 
medium without penicillin and strepto-
mycin, because antibiotics may cause 
undesired toxicity during transfection. 
1.The media over the cells was 
removed.
2.The petridish was washed twice with 
PBS (2 x 10 ml).
3.Trypsin (1 ml, Invitrogen) was added 
to the dish, and the cells were 
incubated (37°C) until they had 
loosened from the dish. This was 
checked in the microscope.
4.LHC-9 medium (5 ml) was added to 
the dish and the cell suspension was 
pipetted to a centrifuge tube and 
centrifuged (1000 rpm, 4 minutes).
5.The supernatant was removed.
6.The pellet was re-suspended in 
LHC-9 without pen./strep. Amount of 
medium used depended on the 
desired dilution of the cells. 
7.Cells were counted using automated 
cell counter (Countess, Invitrogen).
8.2.5x105 cells were seeded in 1 ml 
LHC-9 in each 35 mm well of a six-
well plate.
9.Cells were incubated for 24 hours.
2.3.2. siRNA mediated AHR 
knock-down 
siRNAs are double stranded 
RNA molecules of 21 nucleotides that 
are widely used for gene specific tran-
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script knockdown. After introduction 
into cells, they are processed by the 
cells own RNA interference machinery. 
The dsRNA molecules are usually in-
troduced into the cells by either lipid-
mediated transfection or viral-mediated 
transduction (there are other methods 
as well, but these are the two most 
common). Which one of these meth-
ods that is the best one to use de-
pends on the cell type being studied. In 
this study, a cationic lipid based rea-
gent was used as transfection method 
for the delivery of AHR specific siRNAs 
because of its suitability for delivering 
molecules across a diverse range of 
commonly used cell types. AHR siRNA 
sequences are shown in Table 2.1.
1. Stealth Select RNAi AHR siRNA 
2.49 µl per well in a 6-well plate) 
was mixed with Opti-MEM® I 
Reduced Serum Medium (247.5 µL/
well). 
2. Lipofectamine™ RNAiMAX (4.8 µL/
well) was diluted with Opti-MEM® I 
Reduced Serum Medium (245.2 µL/
well).
3. The diluted siRNA was 
added to the diluted 
Lipofectamine 
RNAiMAX and mixed 
gently and incubated 
for 20 minutes. 
4. Medium was removed 
from the wells and 
DMEM (2 mL) was 
added.
5. The transfection solution was 
carefully dripped over the cells (500  
µL/well) and the plates were gently 
rugged. The final conentration of 
siRNA was 20 nM.
6. Cells were incubated for 48 hours 
(37°C, 5% CO2)
7. The transfection solution was 
removed and the cells were either 
exposed to B[a]P, CSC, or DMSO 
for 1, 3, or 5 days. 
8. Cell culture experiments were 
stopped by placing the multi-dishes 
on ice, removing the medium over 
the cells, followed by washing with 
PBS (3 x 2 mL). The multi-dishes 
were stored at -80°C until RNA-
isolation.
2.3.3.The persistence of 
siRNA mediated gene 
silencing.
To examine the durability of 
siRNA mediated AHR silencing, cells 
where transfected for 48 hours as de-
scribed above, and then stopped im-
Materials and method
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Sequence
AHR fwd 1 CCUUUAAUGGAGAGGUGCUUCAUAU
AHR reverse1 AUAUGAAGCACCUCUCCAUUAAAGG
AHR fwd 2 GAGGCUCAGGUUAUCAGUUUAUUCA
AHR rev 2 UGAAUAAACUGAUAACCUGAGCCUC
AHR fwd 3 CCAAGCGGCAUAGAGACCGACUUAA
AHR rev 3 UUAAGUCGGUCUCUAUGCCGCUUGG
Table	  2.1:	  Sequences	  of	  control	  and	  AHR	  speciﬁc	  siRNA	  used	  in	  AHR	  
knock	  down	  experiment	  in	  HBEC3-­‐KT	  in	  vitro.	  All	  siRNA	  molecules	  
were	  suspended	  in	  1	  mL	  RNase-­‐free	  H2O,	  Tris-­‐HCl	  (10	  mM,	  pH8.0),	  
NaCl	  (20	  mM),	  EDTA	  (1	  mM).
mediately, 1 day, 3 days, or 5 days af-
ter transfection solution was removed. 
2.3.4.Toxicity testing
The CellTiter-Blue® cell viability 
assay (Promega) uses the indicator dye 
resazurin to measure the metabolic 
capacity of cells. Viable cells retain the 
ability to reduce resazurin into re-
sorufin, which is highly fluorescent. 
Nonviable cells rapidly lose metabolic 
capacity, do not reduce the indicator 
dye, and thus do not generate a fluo-
rescent signal.
1.Cells were passaged to two 96-well 
plates (1.1x104 cells/well) and 
incubated (37°C, 5% CO2) for 24 h 
before transfected as described 
earlier (250 µl transfection media).
2.When the transfection medium was 
removed, one plate was added 
LHC-9 medium and incubated for 
another 24 h before toxicity testing. 
The second 96-well plate was added 
LHC-9 (100 µL) and CellTiter-Blue® 
(20 µl) and icubated (4 h).
3.Fluoresence was measured at 
560/590nm (Modulus microplate 
reader, Pronova). 
2.4.RNA-isolation
RNA from both harvested 
mouse lung and from human lung cell 
cultures was isolated using TRIzol-RNA 
reagent, a monophasic solution of 
phenol and guanidine thiocyanate that 
disrupt and homogenise cells and tis-
sues and inhibit RNases. TRIzol-RNA 
isolates total RNA and is thus usable 
for isolation of both mRNA and miRNA. 
Chloroform is added to the TRIzol-RNA 
homogenate and the solution is centri-
fuged, which leads to the separation of 
three phases. The aqueous (upper) 
phase contains RNA, the interphase 
contains DNA, and the organic (lower) 
phase contains proteins. The RNA is 
precipitated with isopropanol 
Protocol
1. The 6-well multi-dishes were taken 
from the freezer and placed on ice. 
Isol-RNA Lysis Reagent (1 mL/35 
mm well) was added. 
2. A cell scraper was used to loosen 
the cells from the plate. The lysate 
from each well was transferred to a 
twist top vial and incubated (room 
temperature, 5 min). 
3. Chloroform (0.2 mL) was added to 
each vial, and the vials were shaken 
by hand for 15 seconds before 
incubated (room temperature, 2-3 
minutes).
4. The vials were centrifuged (12000 
g, 4°C, 15 min).
5. The upper, aqueous phase was 
transferred to a new twist top vial, 
added iso-propanol (0.5 mL) and 
incubated (room temperature, 10 
min). The lower, organic phase was 
discarded.
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6. The vials were centrifuged (12000 
g, 4°C, 15 min).
7. The supernatant was aspirated and 
discarded. 
8. The pellet was washed with ethanol 
(75%, 1mL) and vortexed.
9. The vials were centrifuged (12000g, 
4°C, 5 min).
10.The supernatant was discarded, 
and the pellet was dried (15-20 min) 
in the vial without the cap on.
11.The pellet was re-suspended in 
nuclease free water (10-15 µL, 
depending on the pellet size) and 
put on ice. 
12.The vials were incubated (65°C, 10 
min), spun down, mixed and put on 
ice. 
13.The vials were put in freezer (-80°C) 
for minimum one night. 
14.The RNA-samples were incubated 
(65°C, 10 min). 
15.RNA was stored at -80°C.
RNA consentration
RNA-concentration was determined by 
OD (260 nm/280 nm) in an Eppendorf 
B i o p h o t o m e t e r. K n o w i n g t h e 
concentration of RNA is important to 
obtain correct dilution in further work. 
Nuc le ic ac ids have absorpt ion 
maximua at 260 nm. A 260 absobtion 
of 1.0 is equivalent to 40.0 µg/ml RNA
(and 50.0 µg/ml dsDNA). Pure RNA 
has a 260/280 ratio of 2.0, while pure 
DNA has a ratio of ~1.8. Each sample 
was diluted 70x (1 µL RNA sample + 
6 9 µ L T E - b u f f e r ) b e f o r e O D 
measurement in a quartz cuvette. 
RNA quality 
RNA quality was measured on a 
subset of RNA samples by using Ali-
gent Bioanalyzer RNA 6000 Nano Kit 
(No. 5067-1511). Results are shown in 
Appendix E.
2.5. RT-qPCR
The polymerase Chain Reaction 
(PCR) is a method for amplification of 
DNA-sequences using repeated cycles 
of altering high and low tempera-
tures101. Reverse transcriptase quanti-
tative PCR (RT-qPCR) is a much-used 
method for examining gene expression. 
RT-qPCR uses a fluorescent reporter 
molecule that binds the PCR product 
and reports its presence by fluores-
cence. As the amount of product in-
creases exponentially during the PCR, 
the fluorescent signal also increases 
exponentially, reflecting the amount of 
product produced102. In the work for 
this thesis two different fluorescent re-
porters were used; Hydrolisation 
probes (TaqMan LDA cards, Applied 
Biosystems) for detection of miRNAs in 
mouse lung, and SYBR Green for de-
tection of mRNA and miRNA in immor-
talised human lung cell lines. 
Materials and method
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2.5.1. cDNA synthesis of 
mRNA
Complementary DNA is synthe-
sised from RNA by a Reverse Tran-
scriptase (RT) enzyme. For cDNA syn-
thesis qScript cDNA Synthesis Kit 
(Quanta) was used. This kit contains a 
combination of oligo-dT and random 
primers, a MMLV RT enzyme, and a 
ribonuclease inhibitor protein.
Protocol
1. A master mix was made of qScript 
RT-enzyme (1µL per sample), qScript 
cDNA SuperMix (4 µL per sample), 
and DEPC water (14.0 µL pr. 
sample). An eppendorf tube for each 
RNA-sample was added master mix 
(19 µL) and RNA (1µL). The tubes 
were vortexed. 
2.The eppendorf tubes were incubated 
in the thermal cycler at the following 
program:
• Incubation, 22°C, 5 minutes.
• Synthesis step, 42°C, 30 
minutes.
• Incubation, 85°C, 5 minutes.
• Incubation, 4°C, minimum 5 
minutes.
3.After PCR each tube was added TE-
buffer (80 µL). The cDNA was stored 
at -20°C. 
2.5.2. cDNA synthesis of 
miRNA
For cDNA synthesis of miRNAs, 
miScript kit (Qiagen) was used. Mature 
miRNAs are not poly-adenylated, and 
consequently oligo-dT primers cannot 
be used directly for cDNA synthesis. 
Therefore, poly(A) polymerase is added 
to the mix to synthesize a poly(A) tail on 
all non-coding RNAs. Oligo-dT and 
random primers can then be used for 
cDNA synthesis of non-coding RNAs 
as well as mRNAs. The polyadenylation 
and reverse transcription is performed 
in a single step. The oligo-dT primers in 
the miScript kit have a universal tag 
sequence on the 5’ end, which is 
utilized in qPCR of miRNAs ( section 
2.5.4). 
Protocol
1.RNA templates were thawed on ice. 
miScript RT buffer and RNase free 
water were thawed at room 
temperature
2.The RNA of the biological replicates 
in each experiment was mixed before 
cDNA synthesis. 
3.A master mix was made, containing 
(volume/reaction):
4.miScript RT Buffer, 5X (4 µl)
5.RNase-free-water (14.5 µl)
6.miScript Revese transcriptase (1 µl)
7.Master mix (20 µl) was added to 
empty plastic tubes
8.RNA (0.5 µl) was added to the tubes 
with master mix, vortexed and put on 
ice. 
9.The tubes were incubated in a cycler 
(37°C, 60 min) and then incubated in 
a heating block (95°C, 5 min) to 
inactivate the enzymes.
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10.cDNA was diluted with TE-buffer 
(30 µl) and then stored at -20°C until 
qPCR. 
2.5.3. mRNA qPCR
qPCR of mRNA is performed by 
using two primers in opposite direc-
tions of the desired gene. The primers 
are designed to span introns, such that 
amplification of genomic DNA residues 
in the cDNA sample is avoided.
Protocol
To obtain optimal Cq values be-
tween 20-30 cycles for all genes, the 
cDNA was diluted to appropriate con-
centrations for each gene. β-actin was 
used as a reference gene for normali-
sation of gene expression. This gene in 
stably and highly expressed in most 
cells, and therefore an cDNA amount 
equivalent to 5 ng RNA input in the 
cDNA  synthesis, was used in the 
qPCR react ion. The amount of 
CYP1A1 cDNA was 100 ng since this 
gene has a low expression. For all 
other genes 50 ng were used. Concen-
tration of all primers was 25 pmol/µl.
For mRNA qPCR PerfeCTa 
SYBR Green FastMix, ROX (Quanta) 
was used. This kit contains AccuFast™ 
Taq DNA polymerase, SYBR Green I 
dye, ROX as an internal fluorescence 
reference, along with buffer and stabi-
lisers. 
qPCR of mRNA was setup 
manually in 96-well plates. A master 
mix of 36 µl per sample was made:
• dH2O (12.08 µl)
• 2x PerfeCTa SYBR Green (23.0 µl)
• Primer up (25 pmol/µl, 0.46 µl)
• Primer lo (25 pmol/µl, 0.46 µl)
A 4x dilution sereis was used to 
generate a standard curve. In PCR 
tube strips, 36 µl of master mix was 
added cDNA (10 µl), dH2O (10 µl) for 
non-template control (NTC) or cDNA 
from 4x dilution series (10 µl). All 
samples were run in 2 parallelles of 20 
µl reactions on a 96-well plate. Cycling 
conditions are shown in table 2.1.
Table	   2.1:	   Cycling	   condiIons 	   for	   qPCR	   with	  
PerfeCTa	  kit	  (Quanta).
Step Temperatu
re (°C) 
Time
AccuFast Taq 
polymerase 
activation
95
2 
min.
Denaturation 
of cDNA
95
10 
sec. 40 
cycl
es
Primer 
annealing and 
extension
60
30 
sec.
Melting curve analysis was performed 
at the end of each qPCR to control for 
correct PCR product. 
2.5.4.miRNA qPCR.
RT-qPCR detection of miRNAs 
is performed by using two primers, one 
that is miRNA specific (this is normally 
the entire mature miRNA sequence) 
and the other is a universal primer that 
is complementary to the tag sequence 
added in the cDNA synthesis step. 
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RNU6B was used as reference gene in 
normalisation of relat ive miRNA 
expression. 
Protocol miScript
qPCR of miRNAs was setup 
using pipetting robot (EP-Motion, 
Eppendorf). qPCR was performed in 
384-well plates with reaction volumes 
of 12 µl: 
• 2x QuantiTect SYBR Green PCR Mix 
(6 µl)
• 10x miScript Universal primer (1.1 µl)
• 10x miScript Primer assay (miRNA 
specific, 1.1 µl)
• RNase-free water [1.3 µl)
• Template cDNA (2.5 µl)
Cycling conditions are shown in table 
2.2. Melting curve analysis was 
performed at the end of each qPCR.
Table	   2.2:	   Cycling	   condiIons	   for	   miScript	  
qPCR	  assay	  (Qiagen).	  
Step Temperat
ure (°C) 
Time
HotStart Taq 
Polymerase 
activation
95
15 
min.
Denaturation 
of cDNA
95
10 
sec.
40 
cycl
es
Primer 
annealing
94
30 
sec.
Extension 70
30 
sec.
Normalisation of expression data 
from cell line experiments
Gene expression was quantified 
by calculating relative changes in 
mRNA or miRNA level between sam-
ples. The quantification cycle (Cq) value 
is the cycle number at which the fluo-
rescence in a sample reaches a manu-
ally set threshold. The Cq value for 
each gene of interest (GOI) is normal-
ised with the Cq value of a reference 
gene. 
The Cq determination of the 
threshold level and in consequence the 
accuracy of the quantification results 
are influenced by the amplification effi-
ciency. Changes in the PCR efficiencies 
are caused by RT and PCR inhibitors 
or enhancers, and by variations in the 
RNA pattern extracted. Even small effi-
ciency differences between GOI and 
reference gene generate false expres-
sion ratio103. Therefore, an efficiency 
corrected mathematical model was 
used for calculation of relative expres-
sion for mRNA (Equation 1)104. 
Relative expression = (Eref )
Cq,ref
(Etarget )Cq,target
(1)
Here E is the PCR efficiency, ref is the 
reference gene, and target is GOI. The 
efficiency of the PCR is found by in-
cluding a dilution series for generating 
a standard curve in every qPCR. The 
slope of the standard curve is used to 
calculate the efficiency in Equation 2103.  
E =10−1/slope (2)
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If the amount of PCR product doubles 
at every cycle (E=2) the slope of the 
standard curve will be -3.33. For 
miRNA qPCR no standard curve was 
included and 100% efficiency (E=2) 
was assumed. Fold change was calcu-
lated by dividing relative expression 
values of each sample (B[a]P or CSC 
exposed) on the expression level value 
of the calibrator (DMSO exposed). 
2.5.5.MicroRNA analysis on 
TaqMan® Low-Density 
Arrays (LDA)
Global mouse miRNA expres-
sion profiling was conducted using two 
TaqMan Low-Density (LDA) array cards 
(Applied Biosystems, card A+B version 
3, 4444913). These two LDA cards 
cover almost all known mouse miRNAs 
of Sanger miRBase build 15 65 Each 
TaqMan LDA card consists of 384 
wells containing 375 preloaded mouse 
miRNA targets and six controls – the 
expression of 750 mouse miRNA can 
be quantified simultaneously in the two 
LDA cards. The preloaded TaqMan 
Array is processed in two-step RT-
qPCR. During the first step, total RNA 
(containing small RNA species) is 
reverse-transcribed followed by RT-
qPCR for detection of specific cDNA 
sequence. 
The total RNA isolated from the 
six Ahr-/- mice (three male and three 
female) and six Ahr+/+ mice (three male 
and three female, in total 12 mice, see 
section 2.1) were run in the LDA card 
sets (A+B).  The LDA expression 
measurements were carried out in col-
laboration with Dr. Mogens Kruhøffer, 
CSO, at AROS Applied Biotechnology 
AS, Science Park Skejby, Aarhus, 
Denmark. The raw miRNA expression 
data (the Cq-values) generated for each 
LDA card were further processed at 
STAMI in collaboration with Dr. Nur 
Duale at the Norwegian Institute of 
Public Health.
Normalisation of expression data
High throughput quantitative 
reverse transcriptase PCR (RT-qPCR) 
is becoming a widely used method for 
expression profiling of microRNAs105. In 
such experiments, there are several 
variables that needs to be accounted 
for, such as differences in amount of 
starting material (input cDNA), differ-
ences in enzymatic efficiencies, or dif-
ferences of expression between tissues 
or cells, when conducting a gene ex-
pression experiments106. The variation 
in gene expression data is a combina-
tion of biological and technical varia-
tions, and to reduce the influence of 
the technical differences the gene ex-
pression data should be normalised 
towards one or more references, such 
as reference genes that ideally do not 
vary between the different samples in 
the individual experiment. The purpose 
of normalisation is to reduce the tech-
nical variation within a dataset, ena-
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bling a better appreciation of the bio-
logical variation107.
There are several different ways 
to normalise high-throughput RT-qPCR 
microRNA data, and no one method 
has so far become standard. The most 
used approach is normalisation to a 
reference gene, the same method as 
used in relative mRNA expression 
analysis in RT-qPCR. In miRNA expres-
sion analysis, stably expressed 
miRNAs or other short RNAs, such as 
short-nucleolar RNA (snoRNA) or short 
nuclear RNA (snRNA, for example 
RNU6105,108) are often used for nor-
malisation.
No universal stably expressed 
miRNAs has been established. How-
ever, i t is common to use the 
microRNAs that are most stably ex-
pressed across the samples in each 
experiment for normalisation. There are 
publicly available software’s such as 
GeNorm 106 and NormFinder109, that 
can be used to determine stably ex-
pressed miRNAs.  These algorithms 
identify the miRNAs that are most sta-
bly expressed across all samples in the 
experiment. In this thesis, we used the 
GeNorm which is an extension to Excel 
(Microsoft Office, Microsoft), that iden-
tifies the most stably expressed 
miRNAs and then uses the geometric 
mean of these to calculate a normalisa-
tion factor (NF) for each sample (each 
mouse in this case). The input values in 
GeNorm are quantities, calculated by 
the delta-Cq method where the highest 
relative expression for each gene is set 
to 1 (Equation 3).
Q = 2−(Cq,i −Cq,min ) (3)
In this equation, Q is the calcu-
lated quantity for the gene of interest 
(GOI), Cq,i is the Cq value for sample i, 
and Cq,min is the minimum Cq value for 
the GOI across all samples. The quanti-
ties are then used by the GeNorm ap-
plication to identify the most stably ex-
pressed genes by determining each 
gene’s pairwise variation with all other 
genes as the standard deviation of the 
logarithmically transformed expression 
ratios. By taking the average pairwise 
variation of a particular gene with all 
other control genes an internal control 
gene-stability factor, M, is calculated. 
The miRNA with the lowest M has the 
most stable expression across all sam-
ples. The genes with the highest M is 
stepwise excluded resulting in two 
constitutively expressed reference 
genes that have the most stable ex-
pression in the tested samples. NF is 
then calculated by taking the geometric 
mean of three or more of the most sta-
bly expressed genes. 
The expression level of the GOI 
is then calculated by dividing the GOI 
quantity with the normalisation factor 
(Equation 4).
NQGOI =
QGOI ,i
NFi
(4)
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where NQGOI is the normalised quantity 
value for the gene of interest, QGOI,i is 
the quantity of the gene of interest in 
sample i, and NFi is the normalisation 
factor for sample i. 
Another approach for normalisa-
tion of high-throughput miRNA expres-
sion analysis is normalisation against 
the global mean of microRNA expres-
sion level (see equation 5)107. This ap-
proach, however, assumes that the 
overall expression level of microRNAs 
remains constant under the conditions 
in the experiment. 
Expression level= 2−(Cq,GOI ,i −Cq,GlobalMean,i ) (5)
One advantage of the “Global 
mean” method is that all raw Cq–val-
ues are normalized to the same value, 
making it possible to compare expres-
sion levels of different miRNAs. In con-
trast, in the “GeNorm” method the Cq–
values are first transformed to quanti-
ties, meaning the expression level of 
each gene is calculated relative to the 
highest expression level across all 
samples for that gene. If comparison of 
expression levels between miRNAs is 
not of interest, this is an unimportant 
feature.
Vandesompele and co-workers, 
who also designed the GeNorm algo-
rithm, first described the “Global Mean” 
normalization method in 2009107. They 
argued that the global expression level 
of miRNAs remains constant across all 
samples, and tested this by running 
GeNorm and NorfmFinder on the 
mean. However, the global mean may 
not remain constant across all samples 
for all individual experiments, so it may 
be necessary to evaluate the stability of 
the mean for each experiment. 
In this thesis, normalisation was 
done by both the global mean method 
and by the GeNorm method on the 
mouse miRNA expression data. Statis-
tical analyses were performed on data 
sets normalised by both these meth-
ods and the results were compared to 
increase the robustness of the conclu-
sions. 
In this thesis, normalisation was 
done by both the global mean method 
and by the GeNorm method on the 
mouse microRNA expression data. 
Statistical analyses were performed on 
data sets normalised by both these 
methods and the results were com-
pared to increase the robustness of the 
conclusions. 
2.6.Statistical methods
Statistical analyses were per-
formed using PASW Statistics v.18.0 
(SPSS Inc., IL, USA) and p > 0.05 was 
accepted as statistically significant. 
Watson U2 test was used to evaluate 
whether the data showed a normal 
distribution. Comparison of two groups 
was performed using parametric two-
sample t-test. Comparison of multiple 
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groups was performed using one-way 
ANOVA followed by a post hoc Bonfer-
roni test to allow for multiple compari-
sons. 
To test for differences between 
the sample groups, statistical analysis 
were performed on both the GeNorm 
normalised data set and the global 
mean normalised dataset. T-test was 
performed in PASW Statistics to check 
for microRNAs differentially expressed 
between Ahr+/+ mice and Ahr-/- mice 
independent of sex, and between male 
and female mice independent of geno-
type. 
Two assumptions for the t-test 
and ANOVA are that both groups of 
∆Cq must have Gaussian distributions 
and equal variances. However, these 
assumptions are not valid in many RT-
qPCR experiments using realistically 
small sample sizes. Therefore, as a 
non-parametric alternative to the un-
paired t-test, a Mann-Whitney-
Wilcoxon test may be a more robust 
and appropriate alternative to analyse 
the two pools of ∆Cq-values. On the 
other hand, gene expression data can 
become closer to normal distribution 
after logarithmic transformation making 
a parametric test more appropriate. 
Moreover, on small data sets, the non-
parametric tests lack statistical pow-
er110.
ANOVA analyses the variance 
within and between the groups and 
returns an F-ratio that can be used to 
define a p-value. If the p-value is low (< 
α = 0.05), the null-hypothesis that the 
groups have the same mean is re-
jected. While t-test and Mann-Whitney-
Wilcoxon test can be used for hy-
pothesis testing of two groups, the 
ANOVA is the appropriate test when 
comparing three or more groups. One 
advantage of ANOVA is the possibility 
of post hoc tests, which identifies 
which group differs from each other. 
One-way ANOVA was performed on 
the two normalised datasets with Bon-
ferroni post hoc tests.
2.7.Hierarchical 
clustering and principal 
component analysis 
(PCA)
Hierarchical clustering and prin-
cipal component analysis (PCA) were 
performed using JExpress Pro v.2009 
(MolMine A/S, Bergen, Norway). PCA 
reduces the dimensionality and classi-
fies variables and thus helps to identify 
the variables that contribute most to 
the variation in a dataset111. Hierarchi-
cal clustering subdivides the whole 
group of genes or treatments in such a 
way that similar groups fall into the 
same cluster, whereas dissimilar fall in 
different clusters. This can assist us in 
identifying genes or treatments with 
similar response112. We used the 
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Euclidean distance metric and the av-
erage linkage cluster method.
To visualise differences in the 
expression levels between Ahr+/+ and 
Ahr-/- mice a heatmap was created for 
the expression values of the signifi-
cantly differentially expressed miRNAs 
as identified by t-test or ANOVA. In 
addition, a component variance analy-
sis was performed to identify grouping/
clustering of miRNAs and of the mice. 
2.8. Analysis of miRNA 
expression data
2.8.1.Genome database 
search for AHR response 
elemnts
The AHR/ARNT complex binds 
to specific sites in the promoter region 
of its target genes. There are two iden-
tified binding elements, AHR Response 
Element I (AHRE-I or XRE) and Aryl 
Hydrocarbon Response Element II 
(AHRE-II) (see consensus sequences in 
table Table 2.3). The core binding se-
quence in XRE, GCGTG, is shown in 
bold. A search in the human and 
mouse genomes for AHR/ARNT bind-
ing sites in positions -10,000 bp to + 
1,000 bp of the differentially expressed 
miRNAs was performed for both 
AHRE-I (core and extended sequence) 
and AHRE-II (Mathematica 8, see Ap-
pendix E for search input/search algo-
rithms). No evolutionary conservation 
analysis was performed.
Table	  2.3:	  AHRE-­‐I	  and	  AHRE-­‐II	  sequence.
AHRE-­‐I 5'-­‐T/GNGCGTGA/CG/CA-­‐
3’
AHRE-­‐II 5’-­‐CATG-­‐(N6)-­‐CT/ATG-­‐3’
2.9.miRNA target prediction 
and functional analysis
Predicted targets for the 10 
most significantly differentially ex-
pressed microRNAs were downloaded 
from miRWalk database (available at 
http://www.ma.uni-heidelberg.de/apps
/zmf/mirwalk/index.html). In addition 10 
non-differentially expressed miRNAs 
chosen by random from the remaining 
miRNAs on the LDA cards, were cho-
sen as reference, and predicted targets 
for these were also downloaded. A 
pivot table was created in Excel for 
both the reference gene set and the 
differentially expressed gene set in 
order to identify genes targeted by 
several miRNAs within each set. Genes 
targeted by more than three miRNAs 
were used for pathway-enriched analy-
ses (Metacore GeneGo, Thomson-
Reuters). The resulting table of path-
ways for both differentially expressed 
miRNAs and for the reference miRNAs 
were imported in Excel, and the ratio 
between the p-value between DE 
miRNAs and ref-miRNAs was calcu-
lated for each pathway. 
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3. Results
3.1.MicroRNA 
expression in Ahr 
wild-type and knockout 
mice
3.1.1.Pre-processing of 
miRNA expression raw data
The miRNA expression levels in 
lungs of Ahr wild-type (n=6) and 
knockout (n=6) mice were analysed by 
RT-qPCR on LDA cards. Raw Cq–val-
ues from 750 miRNAs were pre-
processed to remove outliers and 
miRNAs with inadequate measure-
ments. The Cq values equal to 35 cy-
cles were considered as a limit of de-
tection and all Cq values > 35 were 
removed from downstream analysis. In 
addition, filtering criteria for missing 
values was set to 50%, which is the 
minimum percentage of existing values, 
and all the patterns with less than 50% 
existing values were removed. The out-
come of these filtering criteria was a 
miRNA expression matrix consisting of 
565 miRNAs X 12 samples.
From the 565 miRNAs, the 32 
miRNAs with lowest variance were se-
lected in order to identify the most sta-
bly expressed microRNAs using Ge-
Norm. The stability of these miRNAs 
across all samples was analysed by 
calculation of an M-value (see section 
2.5.5). The stability of the global mean 
was also evaluated along with the 32 
miRNAs. The expression levels of 
mammalian RNU6 were found to be 
the most stable across all samples, 
and they were found to be even more 
stable than the global mean (see Ap-
pendix C). The GeNorm software cal-
culated a normalisation factor for each 
sample by taking the geometric mean 
of the quantities of the most stably ex-
pressed microRNAs (see Appendix C). 
The miRNAs were normalised by divid-
ing the miRNA quantity with the NF 
generated by GeNorm. Since the sta-
bilities of mammalian RNU6 were 
higher than the stability of the global 
mean, GeNorm normalised data were 
used for downstream analysis.
3.1.2. Identification of 
differentially expressed 
miRNAs 
Distribution fit tests were per-
formed in Mathematica 8 (Wolfram Re-
search, Inc.) and 24 and 12 miRNAs 
from the wild type and knockout data-
set were identified, respectively, as not 
normal distributed at the 2.5% level 
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(The Mathematica software only per-
forms t-test on datasets that are nor-
mal distributed with p>0.025 according 
to the Watson U2 test). However, due 
to the vast majority of the miRNAs be-
ing normal distributed, t-test was cho-
sen to identify if any of the 565 miRNAs 
showed indications of being differen-
tially expressed between Ahr-/- and 
Ahr+/+. 
The microRNAs found to be sig-
nificantly diffenrently expressed (t-test, 
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miRNA Name p-value
FKO/
FWT
FKO/
MKO
MKO/
MWT
FKO/
MWT
MKO/
FWT
MWT/
FWT
KO/WT
mmu-miR-191* 0.0016 1.42 1.45 1.37 1.06 1.03
mmu-miR-592 0.0029 2.83 2.15 2.46 2.47 2.46
mmu-miR-335-3p 0.0032 0.44 0.34 0.36 0.43 0.39
mmu-miR-141* 0.0058 0.64 0.69
mmu-miR-154* 0.0107 0.53 2.48
mmu-miR-676* 0.0117 0.66
mmu-miR-27a* 0.0148 0.64
mmu-miR-24 0.0167 0.77
mmu-miR-183* 0.0218 0.64
mmu-miR-135a 0.0283 0.46
mmu-let-7b* 0.0295 1.28
mmu-miR-764-5p 0.0302 0.73
mmu-miR-701 0.0304 0.70
mmu-miR-101b 0.0310 0.63
mmu-miR-188-5p 0.0337 0.51
mmu-miR-448 0.0390 0.48
mmu-let-7g* 0.0447 0.61
Table	  3.2:	  Results	  from	  ANOVA	  tesIng	  
on	  miRNA	  expression	  levels.	  A	  Bonfer-­‐
roni	  post	  hoc	  test	  was	  performed	  to	  
idenIfy	  which	  groups	  signiﬁcantly	  dif-­‐
fered	  from	  the	  other	  groups.	  Fold	  
change	  was	  calculated	  by	  dividing	  the	  
relaIve	  expression	  level	  of	  knockout	  on	  
relaIve	  expression	  level	  of	  wild-­‐type	  for	  
each	  group.	  Fold	  change	  is	  given	  only	  
for	  the	  groups	  in	  which	  the	  parIcular	  
miRNA	  was	  found	  to	  be	  diﬀerenIally	  
expressed.	  FKO:	  Female	  knockout,	  FWT:	  
Female	  wild-­‐type,	  MKO:	  Male	  knockout,	  
MWT:	  Male	  wild-­‐type.	  
miRNA Name T-Test
Fold 
Change
mmu-miR-335-3p 2.22E-04 0.39
mmu-miR-592 4.67E-04 2.46
mmu-miR-33* 5.60E-03 0.76
mmu-miR-27a* 2.34E-03 0.70
mmu-miR-210 0.020 0.73
mmu-miR-764-5p 0.020 0.76
mmu-miR-491 0.023 0.78
mmu-miR-188-5p 0.027 0.64
mmu-miR-183* 0.017 0.75
mmu-miR-183 0.025 0.76
mmu-miR-15a* 0.028 0.80
mmu-miR-223 0.028 0.76
mmu-miR-148b 0.041 0.74
mmu-miR-182 0.043 0.74
mmu-miR-547 0.046 0.69
Table	  3.1:	  miRNAs	  signiﬁcantly	  (p<0.05) diﬀeren-­‐
Ially	  expressed	  between	  Ahr	  wild-­‐type	  and	  knock-­‐
out	  mice.	  Fold	  change	  was	  calculated	  by	  dividing	  
relaIve	  expression	  levels	  of	  knockout	  on	  relaIve	  
expression	  levels	  in	  wild-­‐type.
p<0.05) are shown in Table 3.1. Fifteen 
microRNAs were differentially ex-
pressed between Ahr+/+ and Ahr-/- 
mice. Fold change was calculated (see 
appendix B), and only one miRNA 
(miR-592) was found to be up regu-
lated in knockout mice, while all others 
were down regulated. ANOVA test was 
also performed to identify significant 
differences between all four groups in 
the experiment; Ahr+/+ male and fe-
male, and Ahr-/- male and female. P-
values from ANOVA is shown in Table 
3.2.  Fold change for the groups found 
to be significantly 
different from each 
other, identified by 
Bonferroni post hoc. 
is shown in Table 3.2. 
3.1.3. Principal 
component 
analysis and 
clustering
Principal component analysis 
(PCA, Figure 3.1) and Hierarchical clus-
tering (figure 3.2) were performed (J-
Express 2009, MolMine A/S, Bergen, 
Norway) on 42 miRNAs, including 
those differentially expressed (t-test) 
and the miRNAs from the ANOVA with 
p<0.05. For comparison, the 565 
miRNAs were also normalised by using 
the global mean method, and the same 
statistical tests was performed on this 
normalised dataset as for the GeNorm 
normalised dataset. While most of the 
Results
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Figure 3.1:	  Principal	  component	  analysis	  of	  the	  signiﬁcantly	  diﬀeren-­‐
Ially	  expressed	  microRNAs	  as	  deﬁned	  by	  t-­‐tesIng	  of	  both	  GeNorm	  
normalised	  data	  and	  Global	  mean	  normalized	  data	  sets.	  The	  graph	  
shows	  that	  the	  wild	  type	  mice	  (WT)	  clusters	  on	  the	  right	  side	  of	  the	  y-­‐
axis,	  while	  the	  knock	  out	  mice	  (KO)	  clusters	  on	  the	  lec	  side	  of	  the	  y-­‐axis.	  
The	  graph	  indicates	  that	  miR-­‐592	  and	  miR-­‐335-­‐3p	  are	  opposite	  corre-­‐
lated,	  which	  agree	  whit	  miR-­‐592	  being	  signiﬁcantly	  up-­‐regulated,	  and	  
miR-­‐335-­‐3p	  being	  signiﬁcantly	  down	  regulated	  (Table	  3.1).	  WTF:	  wild-­‐
type	  female,	  WTM:	  wild-­‐type	  male,	  KOF:	  knockout	  female,	  KOM:	  
knockout	  male.	  
differentially expressed miRNAs found 
in the global mean dataset overlapped 
with the differentially expressed in the 
GeNorm dataset, 10 addit ional 
miRNAs were found to be differentially 
expressed in the global mean dataset. 
These 10 miRNAs were included in the 
clustering and principal component 
analysis, resulting in a total of 42 
miRNAs. 
The heat-map created for the 42 
miRNAs (Figure 3.2) show that wild-
type and knockout mice are independ-
ently clustered, indicating a difference 
in the expression level dependent on 
the genotype of the mice. This was 
expected since the input data for the 
clustering was already filtered by hy-
pothesis testing. The heat-map sug-
gests that most of the differentially ex-
pressed microRNAs are down-
regulated in Ahr-/- mice compared to 
Ahr+/+ mice, while only a few are up-
regulated. However, the differences in 
expression between the groups appear 
to be rather low. Also, there appears to 
be very little variation in expression lev-
els of these microRNAs between the 
sexes. The clearest pattern in the heat-
map is seen for miR-592 (located at 
the bottom of the map) and miR-335-
3p (located in the middle) which also 
here is shown to be opposite regu-
lated. 
The results of the PCA showed 
that wild type and knockout mice were 
g ro u p e d i n d e p e n d e n t l y. M o s t 
microRNAs clustered together, but 
some microRNAs separated from the 
others. Of interest is miR-592 and miR-
335-3p, which were shown to be op-
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Figure 3.2:	  Heat-­‐map	  showing	  relaIve	  expression	  levels	  of	  microRNAs	  diﬀerenIally	  expressed	  in	  
Ahr+/+	  and	  Ahr-­‐/-­‐	  mice.	  Clustering	  analysis	  separate	  knock	  out	  from	  wild	  type	  mice,	  and	  the	  ﬁg-­‐
ure	  indicates	  a	  tendency	  towards	  most	  of	  the	  signiﬁcantly	  deregulated	  microRNAs	  being	  down-­‐
regulated	  in	  Ahr-­‐/-­‐	  mice.	  WTF:	  wild-­‐type	  female,	  WTM:	  wild-­‐type	  male,	  KOF:	  knockout	  female,	  
KOM:	  knockout	  male.	  
!
posite correlated, in accordance with 
the fold changes of these two miRNAs. 
3.1.4. Selcting miRNAs for 
further analysis
The four most significantly differ-
entially expressed miRNAs, miR-335-
3p, miR-592, miR-33*, and miR-27a*, 
(p<0.01) were chosen for further analy-
sis. All of these miRNAs showed con-
sistent expression patterns in both 
male and female mice (Figure 3.3, for 
information about miNRA sequence 
and chromosome localisation see Ap-
pendix D).
3.1.5. Genome database 
search for AHR response 
elements
Differences in expression of mi-
croRNA’s between Ahr wild-type and 
knockout mice could be associated 
with the occurrence of binding sites for 
the Ahr transcription complex in regu-
latory regions upstream of the particu-
lar microRNA’s. A search for full and 
core consensus AHR response ele-
ment I (AHRE-I), and AHRE-II se-
quences in the promoter region of the 
four most differentially expressed 
miRNAs was performed (Mathematica 
8, Appendix E). Although few perfect 
matches with the full AHRE-I and II 
consensus were found, many core 
binding regions of AHRE-I were pre-
sent in both human and mouse. Since 
no evolutionary analysis was per-
formed, it is not known whether the 
AHREs identified in the two species are 
the same ones. 
3.1.6. Target prediction and 
functional pathway analysis
To identify enriched biological 
processes with mRNA targets of the 
Results
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Figure	  3.3:RelaIve	  expression	  of	  the	  four	  
miRNAs	  with	  lowest	  p-­‐value	  (t-­‐test)	  in	  Ahr+/+	  
and	  Ahr-­‐/-­‐	  mice.	  A:	  Average	  relaIve	  expression	  
in	  male	  and	  female	  combined.	  Fold	  changes:	  
miR-­‐335-­‐3p,	  0.39	  ;	  miR-­‐27a*,	  0.70;	  miR-­‐592,	  
2.46;	  miR-­‐33*,	  0.76.	  B-­‐E:	  RelaIve	  expression	  of	  
each	  miRNA	  shown	  for	  male	  and	  female	  sepa-­‐
rately.	  The	  graphs	  show	  that	  AHR-­‐dependent	  
regulaIon	  is	  consistent	  in	  both	  sexes.	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Table	  3.4:	  Biological	  processes	  where	  the	  predicted	  target	  mRNA	  are	  involved.	  P-­‐values	  calcu-­‐
lated	  in	  MetaCore	  for	  both	  targets	  of	  diﬀerenIally	  expressed	  microRNAs	  and	  reference	  
microRNAs	  are	  shown.	  A	  p-­‐value	  of	  1.0	  is	  set	  for	  pathways	  not	  listed	  as	  targets	  of	  the	  reference	  
miRNAs.	  Speciﬁcity	  raIo	  is	  calculated	  by	  dividing	  the	  p-­‐value	  of	  pathways	  enriched	  with	  refer-­‐
ence	  miRNA	  targets	  on	  p-­‐value	  of	  pathways	  enriched	  with	  diﬀerenIally	  expressed	  miRNA	  tar-­‐
gets.	  DE	  miRNAs:	  DiﬀerenIally	  expressed	  miRNAs,	  Ref	  miRNAs:	  reference	  miRNAs	  selected	  at	  
random.	  
Pathway DE miRNAs Ref miRNAs Specificity Ratio
Development_Gastrin in differentiation of the 
gastric mucosa 3.16E-06 1.0 316456
Signal transduction_cAMP signaling 4.32E-04 1.0 2315
Development_G-Proteins mediated regulation 
MARK-ERK signaling 6.33E-04 1.0 1580
Development_A2B receptor: action via G-
protein alpha s 7.48E-04 1.0 1337
Muscle contraction_ACM regulation of smooth 
muscle contraction 9.38E-04 1.0 1066
Development_Gastrin in cell growth and prolif-
eration 1.15E-03 1.0 870
Immune response_Gastrin in inflammatory 
response 1.42E-03 0.163 115
miRNA Name AHRE-I full
(mmu)
AHRE-I core
(mmu)
AHRE-II full 
(mmu)
AHRE-I 
full (hsa)
AHRE-I 
core (hsa)
AHRE-II 
full (hsa)
miR-27a*
miR-33a*
miR-335*
miR-592
2 10 0 0 7 1
0 8 1 1 13 0
1 10 1 0 7 0
NA NA NA 0 2 1
Table	  3.3:	  A	  search	  for	  AHR	  response	  element	  (AHRE)	  I	  and	  II	  was	  doen	  in	  MathemaIca	  8	  (Wolfram	  
Research,	  Inc).	  Full	  AHRE-­‐I:	  5'-­‐T/GNGCGTGA/CG/CA,	  Core	  AHRE-­‐I	  5'-­‐GCGTG{Swanson:1995wu},	  Full	  
AHRE-­‐II:	  CATG{N6}CT/ATG{Sogawa:2004il}.	  mmu:	  Mus	  musculus,	  hsa:	  Homo	  sapiens.The	  miR-­‐592	  
was	  not	  found	  by	  sequence	  search	  of	  the	  mouse	  genome	  in	  MathemaIca.	  Therefor	  NA	  is	  reported	  
for	  miR-­‐592	  in	  mouse.
differentially expressed miRNAs, func-
tional ontology enrichment analysis 
was performed in MetaCore (GeneGo, 
Thomson Reuters). Ten of the most 
differentially expressed miRNAs, and 
ten reference miRNAs chosen at ran-
dom (by random number generation) 
from the non-differentially expressed 
miRNAs were included in the analysis. 
The predicted mRNA targets of these 
miRNAs were downloaded from miR-
Walk, and all mRNAs predicted to be 
targeted by 3 or more of the chosen 
microRNAs were uploaded to Meta-
Core which then provided a p-value for 
pathways enriched by microRNA pre-
dicted targets. A specificity ratio was 
calculated by dividing the p-value of 
the pathways found to be coregulated 
by the reference microRNAs on the p-
values of targets coregulated by the 
differentially expressed microRNAs. 
Seven pathways were found to be 
overrepresented (specificity ratio > 100) 
i n the d i f f e ren t i a l l y expressed 
microRNAs. 
Most of AHR’s known function is 
in xenobiotic metabolism, although 
AHR is also involved in several other 
biological pathways. AHR regulated 
miRNAs may be important in regulating 
mRNA targets involved in AHR con-
ducted biological pathways. To investi-
gate the interplay between the four 
miRNAs chosen for further studies 
(miR-27a*, miR-33*, miR-335*, and 
miR-592) and proteins known to be 
involved in AHR pathways, a pathway 
map was generated in MetaCore. The 
four miRNAs, AHR, ARNT, and 
CYP1A1 were used as input (Figure 
3.4). 
An interesting notion in this 
pathway map is that miR-335 directly 
inhibits the tumour suppressor gene 
retinoblastoma protein (Rb). It is also 
worth noticing that the hormonal re-
ceptors oestrogen receptor 1 (ESR1) 
and androgen receptor are involved in 
this pathway. Especially, ESR1 is indi-
cated as having a inhibitory effect on 
miR-27a. 
3.2.Cell culture 
experiments
RNA interference experiments,  using siRNA 
targeting Ahr mRNA, were performed to 
investigate the effect of the AHR on seven 
miRNAs in vitro. Four of the miRNAs (hsa-
miR-27a*, hsa-miR-33a*, hsa-miR-335*, 
and hsa-miR-592) were chosen based on 
the effect of the AHR on expression of their 
homologues (mmu-miR-27a*, mmu-miR-
33*, mmu-miR-335-3p, and mmu-miR-592, 
respectively) in the knock out mouse ex-
periment. Three additional miRNAs (hsa-
miR-122a, hsa-miR-203, and hsa-miR-494) 
were chosen based on their previously re-
ported dependence of AHR in the literature. 
3.2.1.Knock Down of AHR 
AHR expression levels were ini-
tially studied in five different immortal-
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ised human lung epithelial cell lines 
(HBEC2-KT, HBEC3-KT, HBEC12-KT, 
BEP2D, and BEAS2B). The cells were 
transfected with three siRNA duplexes, 
each targeting a unique sequence in 
the Ahr mRNA without other compli-
mentary sequences in the human ge-
nome. The reason for using several 
siRNA against the same target is to 
reduce off target effect silencing by a 
single siRNA. To identify knock down 
efficiency of each siRNA and that com-
pared to the mixture of all three siR-
NAs, an experiment was conducted 
were the siRNAs were transfected 
separately, and the mRNA levels of 
AHR was measured by RT-qPCR (fig-
ure 3.5). The results showed significant 
knock down of the AHR. Why the 
effect of separate siRNAs were meas-
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Figure	  3.4:	  A	  biological	  pathway	  map	  was	  created	  in	  MetaCore	  using	  the	  miR-­‐27a,	  miR-­‐33a,	  miR-­‐
335,	  miR-­‐592,	  AHR,	  ARNT,	  and	  CYP1A1	  as	  input	  data.	  The	  map	  shows	  interacIons	  between	  cellu-­‐
lar	  components.	  Green	  arrows	  mean	  acIvaIon,	  red	  lines	  mean	  inhibiIon,	  and	  grey	  lines	  mean	  
that	  the	  funcIon	  of	  the	  interacIon	  is	  unknown.	  ExplanaIon	  of	  symbols	  is	  provided	  in	  Appendix	  H.
ured in BEP2D cells and not HBEC3-
KT is that this was done early in the 
process, before the cell line for further 
experiments was chosen. Optimally the 
this should also have been done in 
HBEC-3KTs. The stability of the siRNAs 
and their knock down effect on AHR 
was studied in HBEC3-KT over 0, 1, 3, 
and 5 days after replacing transfection 
medium with LHC-9 medium (for 0 
days the cell line experiment was 
stopped immediately after removing 
transfection medium). The results 
showed no reduction of silencing po-
tential over time.
3.2.2. Cell morphology after 
siRNA transfection
The cells transfected with AHR 
siRNA were observed to have a differ-
ent phenotype than cells transfected 
with control siRNA in the phase con-
trast light microscope (Figure 3.6). The 
AHR siRNA transfected cells appeared 
bigger and more flattened than their 
c o n t ro l t r a n s f e c t e d a n d n o n -
transfected counterparts. Also, AHR 
siRNA transfected cells contained more 
vacuoles and more cell-cell conjunc-
tions.
3.2.3. Toxicity of AHR siRNA 
transfection
To test for toxicity of the AHR 
siRNAs and the control siRNAs a toxic-
ity assay using cell-titer blue 
was carried out in two different 
cell lines (HBEC3-KT, BEP2D). 
No toxic effect of neither AHR 
siRNA nor control siRNA was 
detected in any of the two cell 
lines (Figure 3.7).
3.2.4. MicroRNA 
expression
To examine the effect of AHR 
on miRNAs in vitro a knock 
down experiment was per-
formed on HBEC3-KT. Cells 
were transfected with either 
AHR siRNA or control siRNA 
and subsequently exposed for 
B[a]P, CSC, or DMSO for 1 or 
5 days. microRNA expression 
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Figure	  3.5:	  BEP2D	  cells	  were	  transfected	  with	  
control	  siRNA,	  a	  mixture	  of	  three	  siRNAs	  target-­‐
ing	  AHR	  mRNA,	  and	  each	  of	  the	  three	  siRNAs	  
independently.	  In	  each	  case	  n=3.	  Expression	  lev-­‐
els	  of	  AHR	  was	  measured	  by	  RT-­‐qPCR.	  RelaIve	  
expression	  levels	  were	  calculated	  using	  the	  PCR-­‐
eﬃciency	  adjusted	  ΔCq	  method.	  Fold	  change	  
(relaIve	  to	  control)	  for	  siRNA	  mix,	  siRNA	  1,	  siRNA	  
2,	  and	  siRNA	  3,	  respecIvely,	  are	  as	  follows:	  AHR:	  
0.14,	  0.16,	  0.27,	  0.11.	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Figure	  3.6:	  A:	  HBEC3-­‐KT	  transfected	  with	  control	  siRNA.	  B:	  HBEC3-­‐KT	  transfected	  with	  AHR	  
siRNA.
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Figure	  3.7:	   Toxicity	   test	   using	   cell	   Iter	   blue	   revieled	  no	   signiﬁcant	   toxicity	   of	   neither	   control	  
siRNA	   nor	   AHR	   siRNA.	   0	  h:	   Cell	   Iter	   blue	   assay	   immediatly	   acer	   transfecIon	  medium	  was	  re-­‐
moved.	   24	  h:	   acer	   removing	   transfecIon	  medium,	   cells	  were	   incubated	   for	  another	  24	  hours	  
before	  cell	  Iter	  blue	  assay	  was	  carried	  out.	  Background	  ﬂuoresence	  is 	  subtracted	  from	  the	  shown	  
values.
levels was measured at two time 
points, one and five days of exposure. 
The experiment was repeated three 
times independently, with two parallel's 
of each sample. 
AHR and CYP1A1 expression 
were measured for each sample by RT-
qPCR to control for knockdown effect 
of siRNA. CYP1A1 mRNA level was 
used as a control for reduced capacity 
of AHR mediated induction (Figure 3.8). 
In addition, ARNT expression was 
measured in one of the experiments. 
For the miRNAs, total RNA from 
the two parallel's within each experi-
ment were combined before cDNA 
synthesis, giving three biological repli-
cates for each exposure at each time 
point. 
The difference in AHR mRNA 
levels between AHR siRNA transfected 
and control cells varied from each ex-
periments, with fold changes ranging 
from as little as 1.26 to 22.19. CYP1A1 
was found to be strongly induced by 
exposure of B[a]P or CSC as com-
pared to control cells, AHR resulted in 
obliteration of CYP1A1 expression in all 
cells. The ARNT was not significantly 
affected by AHR silencing in this ex-
periment. 
Expression levels of seven 
miRNAs were measured, three se-
lected from previous reports, and four 
selected from the AHR knock out mice 
experiment in this theses. No signifi-
cant differences were found in the four 
miRNAs chosen from the knock out 
experiment (Figure 3.9). For the 
miRNAs previously described in the 
literature, miR-122a and miR-203 were 
significantly down-regulated in AHR 
siRNA cells compared to control (Fig-
ure 3.10). miR-203 was also signifi-
cantly down-regulated in cells exposed 
to B[a]P or CSC for five days com-
pared to control (DMSO). 
Results
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Figure	  3.8:	  A:	  Stability	  of	  AHR	  siRNA	  in	  HBEC3-­‐KTs	  cultur d	  for	  for	  0,	  1,	  3,	  or	  5	  days	  acer	  transfecIon	  me-­‐
dium	  is	  replaced	  with	  LHC-­‐9	  medium.	  Fold	  changes	  are:	  0	  days:	  0.23	  (p=6.14x10-­‐6),	  1	  day:	  0.76	  (p=0.21),	  3 	  
days:	  0.11	  (p=4.7x105),	  5	  days:	  0.12	  (p=0.0024).	  Signiﬁcant	  knockdown	  (t-­‐test,	  p<0.05)	  is	  indicated	  by	  an	  
asterisk.	  B-­‐F:	  Expression	  levels	  of	  ARNT,	  AHR,	  and	  CYP1A1	  in	  HBEC3-­‐KTs	  transfected	  with	  AHR	  siRNA	  or	  
control	  siRNA.	  Note	  that	  the	  lower	  and	  upper	  half	  of	  the	  CYP1A1	  axes	  have	  diﬀerent	  dimensions.	  The	  fold	  
changes	  for	  DMSO,	  B]a]P,	  and	  CSC,	  respecIvely,	  is:	  ARNT:	  0.9	  (p=0.051),	  1.2	  (p=0.07),	  1.3	  (p=0.36)	  AHR:	  
2.8	  (p=0.003),	  1.9	  (p=014),	  1.3	  (p=0.25),	  CYP1A1:	  6.1	  (p=0.004),	  126.6	  (p=0.043)	  44.4	  (p=0.047).
F
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Figure	  3.9:	  Four	  diﬀerenIally	  expressed	  miRNAs	  were	  chosen	  from	  the	  knock	  out	  mice	  experiment	  and	  
their	  expression	  levels	  were	  measured	  in	  HBEC3-­‐KTs	  by	  RT-­‐qPCR.	  None	  of	  the	  miRNAs	  were	  found	  to	  be	  
signiﬁcantly	  (p<0.5,	  3-­‐way	  ANOVA)	  aﬀected	  by	  neither	  AHR	  silencing,	  exposure,	  duraIon,	  nor	  any	  combi-­‐
naIon	  of	  the	  treatments.
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Figure	  3.10:	  The	  expression	  levels	  of	  three	  miRNAs	  previously	  found	  to	  be	  aﬀected	  by	  exposure	  of	  B[a]P	  
were	  invesIgated	  in	  HBEC3-­‐KTs.	  Expression	  of	  miR-­‐122a	  was	  found	  to	  be	  signiﬁcantly	  down	  regulated	  
(p=0.00012)	  in	  AHR	  siRNA	  transfected	  cells.	  miR-­‐203	  was	  found	  to	  be	  signiﬁcantly	  aﬀected	  by	  siRNA	  
transfecIon	  (control	  vs.	  AHR	  siRNA,	  p=0.0015),	  exposure	  (B[a]P	  and	  CSC	  compared	  to	  DMSO,	  p=0.0002),	  
and	  by	  duraIon	  of	  exposure	  (p=0.00003).	  miR-­‐494	  expression	  was	  signiﬁcantly	  altered	  by	  exposure	  
(B[a]P	  compared	  to	  DMSO,	  p=0.023),	  and	  by	  duraIon	  of	  exposure	  (p=0.018).	  
4.Discussion
Little is known about epigenetic 
mechanisms in toxic effects of envi-
ronmental pollutants. MicroRNAs are 
involved in many, if not all, biological 
processes and function as down-
regulators of gene expression by se-
quence specific targeting of mRNAs. 
Aberrant expression of several miRNAs 
has been observed in different types of 
cancer, including lung cancer113,88. 
Emerging evidence suggest that 
miRNA expression can be regulated by 
environmental factors84. How environ-
mental factors influence epigenetic 
changes is still largely unclear. In-
creased knowledge of the mechanism 
by which environmental compounds 
lead to changes in the epigenome will 
lead to increased insight into their pos-
sible carcinogenic effects. 
In this thesis, the effect of the 
AHR on miRNA expression was exam-
ined. The most studied and most un-
derstood biological pathway in which 
AHR is involved, is xenobiotic metabo-
lism. AHR binds exogenous planar 
polyaromatic ligands, such as PAHs, 
which among others are present in 
tobacco smoke, and dioxin like com-
pounds. Ligand binding to the AHR 
leads to an activated transcription fac-
tor that ultimately induces transcription 
of among others phase I and phase II 
xenobiotic metabolising genes. In-
creasing evidence suggests that the 
AHR is involved in a wide range of bio-
logical processes including develop-
ment, cell cycle regulation, cell signal-
ling, cytoskeleton organisation, extra 
cellular matrix (ECM) modification, ad-
hesion, immune responses, and cir-
cadian rhythm34,40-43. Accumulating 
evidence for importance of the AHR in 
a diverse range of biological processes 
underlines the need to identifying 
miRNAs regulated by this transcription 
factor. Since miRNAs are transcribed 
by RNA pol II, they are classified as 
class II genes, and can be transcrip-
tionally regulated by transcription fac-
tors that regulate transcription of this 
class of genes, such as the AHR. We 
hypothesised that the AHR may medi-
ate some of its biological function by 
regulating the expression of certain 
miRNAs, and aimed at identifying such 
miRNAs. 
An initial high-throughput RT-
qPCR screening of the expression of 
750 miRNAs in mouse lung was per-
formed to identify candidate miRNAs 
whose expression potentially is regu-
lated by AHR. Fifteen miRNAs were 
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found to show significantly different 
expression in Ahr-/- compared to Ahr+/+ 
mice. Although the fold change for 
most of the miRNAs was relatively low, 
the biological consequences could be 
significant due to each miRNA being 
able to target several mRNAs86. In ad-
dition, if the miRNAs regulated by AHR 
act on the same biological pathways 
the cumulative effect could be of sig-
nificance. 
To identify pathways that may be 
co-regulated by differentially expressed 
miRNAs in the knockout mouse ex-
periment, a functional ontology enrich-
ment analysis was performed in Meta-
Core (GeneGo, Thomson-Reuters). 
Seven biological processes were found 
to be enriched with targets of 10 se-
lected miRNAs. Interestingly, six of 
these pathways are related to G-
protein mediated signalling. As men-
tioned previously (section 1.3.2), G-
protein mediated signalling can nega-
tively regulate AHR activity. G-protein 
coupled receptors (GPCR) play an im-
portant role in cancer progression and 
metastasis. Disruption of normal GPCR 
functionality in tumours can lead to 
autonomous cell proliferation, evading 
immune cell detection, increase in nu-
trient and oxygen supply, invading of 
surrounding tissues, and dissemination 
to other organs114.
Gastrin releasing peptide (GRP) 
stimulates cell proliferation and growth 
through the GPCR family member GRP 
receptor (GRPR). GRP has been 
shown to be important in tumourigene-
sis and is overexpressed in lung tu-
mors25,115. An increase in expression of 
GRPR mRNA in human lung has been 
shown to be associated with smoking, 
and even more so in female smokers 
than in male smokers116. 
 Since there seem to be a com-
peting role between TCDD and G-
protein activated AHR38,39, it may be 
hypothesized that miRNAs can medi-
ate repression of mRNAs involved in G-
protein signalling in the presence of 
exogenous ligands, in order to sup-
press G-protein mediated inhibition of 
AHR. This would make more AHR 
available for ligand binding and XME 
induction, increasing metabolic capac-
ity. 
All but one of the differentially 
expressed miRNAs were down regu-
lated. The AHR/ARNT complex in-
duces transcription by binding to AHR 
responsive elements (AHRE I or AHRE 
II).  The down regulation of certain 
miRNAs in the absence of AHR, sug-
gests that these miRNAs might be 
transcriptionally induced by direct bind-
ing of AHR/ARNT complex to AHRE in 
their promoter region. A loss of AHR 
functionality would then lead to re-
duced expression of these miRNAs. 
Another explanation would be that 
transcription of these miRNAs is in-
duced by other transcription factors 
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downstream of AHR in the AHR path-
way. 
Four miRNAs from the mouse 
experiment (miR-27a*, miR-33*, miR-
335-3p, and miR-592), were chosen 
for further studies in human lung cell 
lines. The three first mentioned miRNAs 
were found to be down-regulated in 
Ahr-/- mice compared to Ahr+/+ mice. 
To determine if the AHR-dependent 
regulation could be explained by AHRE 
located in the promoter region of these 
three miRNAs, a search for full and 
core AHRE-I and full AHRE-II se-
quences was performed. Few full 
AHRE-I or AHRE-II were found in the 
human and mouse genome in pro-
moter regions of these miRNAs. How-
ever, many core AHRE-II sequences 
were found and some of these differed 
in as little as one nucleotide from the 
full sequence. If the AHR/ARNT-
complex is able to bind to the core 
sequence without full consensus simi-
larity of the flanking sites, there is a 
possibility that one or more of the ele-
ments found could be responsible for 
inducing transcription of one of the 
microRNAs. For these miRNAs, how-
ever, this has not been demonstrated 
experimentally.
The AHRE-I core sequence is 
five nucleotides long which means that 
if randomly distributed in the genome, 
it would be expected to occur once 
every kilo base. A search for AHRE-I 
core sequence in the entire chromo-
some 6 (126 Mb) in the mouse ge-
nome, for example, results in only 
28,000 AHRE-I core sequences found, 
giving an expected occurrence every 
fourth kilo base. This suggests that 
since the five nucleotide AHRE-I core 
sequence has a biological function, it 
has been selectively conserved in re-
gions close to genes that depend on 
AHR for appropriate transcription, while 
at the other hand, selectively removed 
through evolution from genomic re-
gions where it may result in aberrant 
transcription of nearby genes. 
The only miRNA upregulated in 
Ahr-/- mice compared to Ahr+/+ mice 
was miR-592. Since AHR functions as 
a transcriptional inducer by direct bind-
ing of response elements upstream of 
transcription start sites of its target 
genes, it is unlikely that transcription of 
this miRNA is directly regulated by 
AHR. The induction of mir-592 tran-
scription may be caused transcriptional 
up-regulation by other bHLH/PAS fam-
ily proteins that might compete with 
AHR for dimerisation to ARNT. It may 
be hypothesised that in the absence of 
AHR, ARNT will then be free to dimer-
ise with these transcription factors, 
thus leading to an increased expres-
sion of miR-592.
miR-27a* was found to be sig-
nificantly down-regulated in both male 
and female Ahr-/- mice. This miRNA 
has previously been reported to be 
significantly up-regulated in SCLC117, 
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gastric cancer118, and prostate can-
cer119, and down-regulated in multi-
drug resistant human ovarian cancer 
cells120. The indication of miR-27a be-
ing deregulated in several types of 
cancer suggests that it might be of 
importance for tumour cells to either 
obtain or sustain their cancerous state. 
miR-27a* is found to target the 
mRNA of a zinc finger protein, 
ZBTB10, that acts as a repressor of 
specificity proteins (Sp)121. The Sp-1 
transcription factor is involved in induc-
ing transcription of oestrogen receptor 
1 (ESR1, also known as ER-α), thus 
miR-27a* mediated repression of the 
Sp-1 repressor results in induced ex-
pression of ESR1 protein122. The miR-
27a has been found to be down-
regulated by estradiol (E2), caused by 
direct inhibition of mir-27a transcription 
by ESR1. Four ESR1 binding sites are 
found in the promoter region of the mir-
23a~mir24~mir27a gene cluster123. 
Oestrogen may be involved in lung car-
cinogenesis. Oestrogen receptors have 
been associated with an increased 
metabolic activation of PAHs in lung 
tissues, and there is evidence for 
cross-talk between ESR and AHR 
124,125. Lung tumors from women are 
more likely to express ESR than lung 
tumours from men, and hence may 
account for some of the sex differences 
in susceptibility to lung cancer25. The 
cross-talk between AHR and ESR 
pathways may involve miRNAs, and 
miR-27a* may be a putative mediator 
of this cross-talk. 
Little literature exists on neither 
mmu-miR-335-3p, nor its human 
homologue hsa-miR-335*. In contrast, 
a few studies have been performed for 
the hsa-miR-335 (major) sequence. 
Expression of mir-335 has been found 
be significantly correlated with tran-
scription of its host gene MEST, indi-
cating a dependent transcriptional 
regulation of these two genes126. The 
possible Ahr dependent regulation of 
miR-335-3p found in this thesis is in-
teresting in relation to previous reports 
where it was up-regulated in a TP53 
dependent manner as a response to 
DNA damage127. The RB1 mRNA is 
directly targeted and down-regulated 
by miR-335, resulting in cell cycle ar-
rest127. This hints at a possibility that in 
the presence of carcinogenic AHR 
ligands, the AHR may induce miR-335 
transcription in order to rapidly down-
regulate RB1 mRNA which gives DNA 
repair enzymes time to remove DNA 
adducts before cell cycle progression 
and DNA replication. The AHR may 
regulate expression of miR-335 directly 
by AHRE binding, or indirectly through 
crosstalk with TP53. However, how 
these hypothesis might relate to miR-
335-3p/miR-335* is not known.
The mir-33a is located in an in-
tron of the sterol regulatory element 
binding transcription factor 2 (SREBF2), 
a transcription factor that controls cho-
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lesterol biosynthesis and uptake by 
stimulating transcription of sterol-
regulated genes. Expression of mir-33 
is co-regulated with the expression of 
SREBF2, and the miRNA functions in 
concert with its host gene to regulate 
cholesterol homeostasis128. Down-
regulation of miR-33 has been ob-
served in lung cancer129. The AHR-
dependent regulation observed in the 
mouse experiment in this thesis sug-
gests that miR-33* may mediate AHR-
dependent tumour suppression.
No studies exist on the specific 
function of miR-592. Two of the highest 
scoring predicted targets of this miRNA 
are involved in immune system func-
tions. Glia maturation factor β (GMFB) 
is involved in T-cell maturation130, while 
tumour necrosis factor (ligand) super-
family member 18 (TNFSF18) is in-
volved in T-lymphocyte survival in pe-
ripheral tissues. How this might relate 
to lung cancer is not known.
 The PCA and clustering analysis 
grouped the wildtype and knockout 
mice separately. However, the dataset 
used for these analyses was already 
filtered by statistical testing (t-test and 
ANOVA), so the observed grouping is 
not evidence of global effects, but 
rather expected from the input dataset. 
Even so, the PCA gives information of 
outlier miRNAs different from the major 
group and their correlation. The heat-
map emphasise the downregulation of 
the majority of differentially expressed 
miRNAs. 
The expression levels of the four 
miRNAs chosen for further studies 
were investigated in an RNA interfer-
ence experiment. Human bronchial 
epithelial cells (HBEC3-KT), a lung cell 
line immortalised by over-expression of 
CDK4 and hTERT showing a “normal” 
phenotype100, was transfected with 
siRNAs specific for AHR receptor100. 
Cell lines may not be an ideal model 
system due to disadvantages like ge-
netic instability, selective growth of 
subpopulations during culturing, and 
lack of microenvironment and other in 
vivo interactions. However, cell lines are 
invaluable as a complement to animal 
studies, and can provide for instance 
provide invaluable knowledge of 
mechanisms of cancer origins131.
 The HBEC3 cell line has been 
reported to be cultured for more than 
240 populations without losing normal 
phenotype, demonstrating its stability 
over several division cycles131. This is in 
contrast to cancer cell lines where it 
can be expected to find thousands of 
mutations and a high degree of ge-
nome instability that might lead to rap-
idly changing phenotypes132. One con-
cern by using HBEC3-KT in the work 
for this thesis is that CDK4 is known to 
form a complex with AHR, and might 
be competing with ARNT for AHR 
binding. This would result in reduced 
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expression of AHR/ARNT complex tar-
get genes.
Transfection of AHR specific 
siRNA resulted in stable knock down of 
AHR mRNA for at least 5 days. Al-
though the AHR protein level was not 
measured, CYP1A1 expression and 
induction was almost completely ab-
lated in AHR siRNA transfected cells, 
suggesting a significantly reduced level 
of AHR transcriptional inducing activity 
in these cells. The knockdown was not 
complete, resulting in a low level of 
induction of CYP1A1 also in trans-
fected cell, however, this was to a sig-
nificantly lesser extent than in untrans-
fected cells. The mRNA level of AHR 
decreased in B[a]P and CSC exposed 
cells. This agree with previous studies 
were reduction of AHR protein have 
been observed upon B[a]P133.
Along with the four miRNAs from 
the mouse experiment, three additional 
miRNAs, miR-122a, miR-203, and 
miR-494, were selected from the litera-
tu re based on repor ted AHR-
dependent transcriptional induction in 
vitro (see section 2.2). In the RNA inter-
ference experiment in this thesis, miR-
122a and miR-203 were shown to be 
down-regulated in AHR knockdown 
cells. The expression of miR-494 was 
not significantly altered by AHR siRNA 
transfection, however, the Cq values of 
this miRNA were very low (<15), mean-
ing that a lower amount of RNA should 
optimally have been used for the RT-
qPCR. Unfortunately, lack of time did 
not allow for a rerun of this miRNA for 
this thesis.
Although miR-122a and miR-
203 were downregulated in the 
absence of AHR, exposure to B[a]P 
and CSC did not significantly induce 
transcription of these miRNAs. As 
mentioned in section 1.3.2, G-proteins 
can directly sequesters AIP from the 
AHR complex, which result in ubiquiti-
nation and nuclear translocation of 
AHR39. Although this was found to re-
sult in AHR having an inhibitory func-
tion on CYP1A1 induction, it is un-
known whether the ubiquitinated AHR 
can form complex with other bHLH/
PAS family members and induce tran-
scription from other response elements 
than those bound by AHR/ARNT com-
plex. Different ligands of AHR have 
been shown to induce transcription of 
different target genes134. This observa-
tion may be caused by AHR dimeriza-
tion to different bHLH/PAS dependent 
on the bound ligand. AHR’s ability to 
bind different partners in the transcrip-
tion regulatory complex may be due to 
conformational changes in AHR protein 
structure caused by ligands with 
slightly different structure 135. It might 
be speculated that induction of miR-
122a and miR-203 may be dependent 
on other exogenous or endogenous 
ligands, and AHR dimerising with other 
proteins than ARNT.
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Levels of miR-203 was signifi-
cantly lower in B[a]P and CSC exposed 
cells after five days compared to con-
trol cells. This can be explained by the 
down-regulation of AHR mRNA ob-
served in exposed cells. If transcription 
of this miRNA is induced in an ARNT 
independent manner, it is also possible 
that introduction of xenobiotics result in 
competitive dimerisation with ARNT.
The four differentially expressed 
miRNAs in Ahr+/+ and Ahr-/- mice cho-
sen for further validation experiments, 
were not found to be differentially ex-
pressed in HBECs in vitro. The reason 
for this lack of correspondence could 
be due to differences between mouse 
and human experimental systems, 
however, the miRNAs chosen from the 
literature were also from mouse data 
and these showed similar results in 
human cells. The previous work on the 
three miRNAs from the literature was in 
vitro data. This might suggest that the 
reason for lack of reproducibility be-
tween mice and human in this thesis 
could be due to differences between in 
vivo and in vitro situations, rather than 
species differences. 
The observed differences in 
miRNA expression between Ahr 
knockout and Ahr wild type mice are 
identical in male and female individuals, 
strongly supporting that these findings 
are real. Moreover, the biological proc-
esses that the identified miRNAs are 
involved in can be tied to AHR function, 
corroborating the notion that these 
miRNAs may be involved in mediating 
some of the biological effects of the 
Ahr in vivo.
The cells transfected with AHR 
siRNA were observed to have a differ-
ent phenotype than cells transfected 
with control siRNA in the phase con-
trast light microscope. The AHR siRNA 
transfected cells appeared bigger and 
more flattened than their control trans-
fected and non-transfected counter-
parts. Also, AHR siRNA transfected 
cells contained more vacuoles and 
more cell-cell conjunctions. This is in 
accordance with previous findings that 
Ahr-/- murine fibroblasts exhibit a more 
spread morphology, associated with 
prominent actin stress fibres and to 
increased numbers of focal adhesions 
with a depolarised distribution around 
the cell area40. The AHR is involved in 
altering the extracellular matrix (ECM) 
and adhesion, and is associated with 
enhance migration and invasiveness42. 
The small (or lack of) effect of 
exposure on the expression of miRNAs 
in vitro is consistent with previous re-
ports on the effect of B[a]P and TCDD 
on miRNA expression. This could sug-
gest that epigenetics, and miRNAs 
specifically, are not important in medi-
ating toxic effects of PAHs. However, 
diesel exhaust particles (DEP), of which 
the organic adsorbents (and particular 
PAHs) are considered to play the im-
portant role in toxicity, have been re-
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ported to induce considerable changes 
on miRNA expression. Jardim et al. 
found that 130 miRNAs, including miR-
494, had increased expression higher 
than 1.5-fold, and 67 miRNAs, includ-
ing miR-27a, had more than a 1.5-fold 
decrease in expression upon exposure 
to DEP in human lung cells in vitro136. 
DEPs adsorb different types of toxic 
compounds, including PAHs. It is pos-
sible that regulation of miRNA by DEP 
(or PAH on the particles) could both be 
a result of AHR activation, but possibly 
by different ligands forming different 
transcription factor complexes 134.  
Further studies
The mouse experiment was just 
performed once so it would be interest-
ing to rerun the TaqMan array on an-
other set of Ahr+/+ and Ahr-/- mice to 
verify the reproducibility of the data. 
Also, it would be interesting to profile 
miRNA expression in lung from mice 
exposed to B[a]P and/or CSC. This will 
provide information whether the same 
miRNAs found to be AHR dependent in 
this thesis are also induced by expo-
sure, or if exogenous ligand activated 
AHR induce transcription of a different 
set of miRNAs. This information can 
provide important insight into how AHR 
may mediate some of the carcinogenic 
effect of xenobiotics, either by induc-
tion of a new set of miRNAs, or by dis-
ruption of intrinsic endogenous AHR 
function. 
In this thesis miRNA expression 
was only studied in one human lung 
epithelial cell line. Further studies 
should include one or more additional 
lung cell lines, for example immortal-
ised by different means, and could also 
include tumour cell lines. Since AHR 
dependent miRNA expression may 
differ in vitro and in vivo, it would be 
interesting to run expression profiling 
arrays on cell lines as well. The time 
span of exposure could be extended to 
see if miRNA expression changes over 
periods longer than five days. Different 
dosages of PAH/CSC would also be of 
interest. Additionally, it would be very 
interesting to expose the cells to other 
PAHs than B[a]P, for instance nitro-
PAHs, to see if different AHR ligands 
can induce expression of different sets 
of miRNAs. 
The next step would be to assay 
the functionality of the identified 
miRNAs. This could be done either by 
screening of mRNA expression, or by 
RT-qPCR of some of the predicted tar-
gets of each miRNA. It would be natu-
ral to include miRNA inhibitors and 
miRNA mimics in these assays, knock-
ing down or over-expressing miRNA 
activity, respectively. 
Whether the AHRE identified in 
this thesis are functional is not known. 
Chip-on-Chip studies may be per-
formed to find out whether any of the 
AHRE elements in the promoter region 
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of the miRNAs are true AHR/ARNT 
complex binding elements.
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5.Conclusion
The aim of this thesis was to identify miRNAs potentially regulated by AHR. 
This was done by initial miRNA expression profiling in lung of Ahr wild type and Ahr 
knockout mice. The biological pathways in which the identified miRNAs may be 
involved were studied by a bioinformatic approach. Four miRNAs from the mouse 
experiment, whose expression were most significantly divergent, together with 
three miRNAs previously reported to be regulated by the Ahr in murine cells, were 
studied in an RNA interference (RNAi) experiment in immortalised human lung 
epithelial cell lines. It was shown that expression of several miRNAs possibly is 
regulated in an AHR-dependent manner. Discrepancies between in vivo and in vitro 
experiments suggest that care must be taken when extrapolating miRNA expres-
sion data from cell culture studies to whole organs or organisms.
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II 
A.Materials
Kits
Kit name Manufacturer (catalogue No.)
RNA quality Agilent RNA 6000 Nano Kit Agilent (5067-1511)
RT-qPCR
mRNA cDNA synthesis qScript™ cDNA Synthesis Kit Quanta (95047-500)
mRNA qPCR PerfeCTa SYBR Green Fast Mix, 
ROX™
Quanta (95073)
miRNA cDNA synthesis miScript Reverse Transcription Kit Qiagen (218061)
miRNA qPCR miScript SYBR Green PCR Kit Qiagen (218073)
RNA interference Invitrogen,
Transfection Lipofectamine™ RNAiMAX 13778100
Negative control Stealth RNAi™ siRNA Hi GC 12935-400
Negative control Stealth RNAi™ siRNA LO GC 12935-200
AHR siRNA Stealth Select RNAi™ siRNA, Set 
of 3
1299003
PCR Primers
Sequece Maufacturer (catalogue No.)
Actin Up 5' GCGAGAAGATGACCCAGATCA DNA Technology A/S
Actin Lo 5' GATAGCACAGCCTGGATAGCAA DNA Technology A/S
AHR Up 5' CCCTTGGAAATTCATTGCCA DNA Technology A/S
AHR Lo 5' GGAGAGGTGCTTCATATGTCGTC DNA Technology A/S
CYP1A1 Up 5' CATCCCCCACAGCACAACA DNA Technology A/S
CYP1A1 Lo 5' CAGGGGTGAGAAACCGTTCA DNA Technology A/S
ARNT Up 5' TTCGTGAGCAGCTTTCCACTT DNA Technology A/S
ARNT Lo 5' TCTCATGGAAGACTGCTGACCTT DNA Technology A/S
AHRR Up 5' GAAGGGACGATATTTTATGCATCAG DNA Technology A/S
AHRR Lo 5' CACGTGGATGTAGTCATAAATGTTCTG DNA Technology A/S
III
Sequece Maufacturer (catalogue No.)
hsa-miR-27a* 5' UUCACAGUGGCUAAGUUCCGC Qiagen (MS00003241)
hsa-miR-33a* 5' GUGCAUUGUAGUUGCAUUGCA Qiagen (MS00003304)
hsa-miR-335* 5' UUUUUCAUUAUUGCUCCUGACC Qiagen (MS00009464)
hsa-mIR-592 5' UUGUGUCAAUAUGCGAUGAUGU Qiagen (MS00004914)
hsa-miR-122a 5' UGGAGUGUGACAAUGGUGUUUG Qiagen (MS00003416)
hsa-miR-203 5' GUGAAAUGUUUAGGACCACUAG Qiagen (MS00003766)
hsa-miR-494 5'UGAAACAUACACGGGAAACCUC Qiagen (MS00004340)
Instruments
Cell 
Counter
Countess automated cell 
counter, Invitrogen
Spectrophotom
eter
Eppendorf Biophotometer
Centrifuge
s
Eppendorf Centrifuge 5702 Microscope Nikon Diaphoto light 
microscope
Sigma 2-6E Multimode 
reader
Modulus Microplate 
Reader, Pronova
Cooler 
centrifuges
Eppendorf Centrifuge 5417R qPCR 
instrument
ABI Prism 7900 HT 
Sequence Detection 
System, Applied 
Biosystems
Sigma 4K15 Thermal cycler Perkin Elmer Cetus DNA 
Cycler 480
Heating 
block
Grand instruments QBT2 Pipette robot Eppendorf EP-Motion
Data software
PASW Statistics 18.0 (IBM SPSS, Somers, NY, USA)
SDS Software 2.4 (Applied Biosystems, Carlsbad, CA, USA)
Mathematic 8 (Wolfram Research, Champaign, IL, USA)
J-Express 2009 (MolMine A/S, Bergen, Norway)
Microsoft Office 2011 Excel (Microsoft Corporation, Redmond, WA)
MetaCore (GeneGo, Thompson Reuters, St. Joseph, MI, USA)
IV
Cell culture media
GIBCO® 
Opti-MEM® I 
Reduced-Serum 
Medium
HEPES buffer, 2,400 mg/L sodium 
bicarbonate, hypoxanthine, thymidine, 
sodium pyruvate, L-glutamine, trace 
elements, and growth factors, no phenol 
red.
Invitrog
en
11058-0
21
GIBCO® D-
MEM⁄F-12
Contains 15 mM HEPES buffer, and 
L-glutamine, no phenol red
Invitrog
en
11039-0
21
GIBCO® LHC-9 
Serum-free medium
L-glutamine, Serum-free, phenol red Invitrog
en
 
12680-0
13
Chemicals
Acetic Acid (glacial) Merck KCl Merck
CellTiter-Blue® Cell Viability 
Assay
Promega L e i b o v i t z ' s L 1 5 
media
Invitrogen
Chloroform Sigma Aldrich MgSO4 Sigma Aldrich
Collagen NaCl Merck
Dimethylsulfoxid Sigma Aldrich NaOH Merck
DNase I (bovine pancreas) Sigma Aldrich NaHPO4* H2O Merck
EDTA (Triplex III) Merck N,N,N',N'-tetra-met
hyl-ethylendiamin 
(TEMED)
Ethanol (rectified, absolute) Kemethyl Penicillin 
Streptomycin
Gibco
Fetal Bovine Serum (FBS) Gibco Phenol red Sigma Aldrich
GelRed Biotium Inc. Propane-2-ol 
(isopropanol)
Merck
Glyserol Thapsigarin Sigma Aldrich
HEPES Sigma Aldrich Tris Base 7-9® Sigma Aldrich
HCl Merck Trypan Blue Stain Invitrogen
TRIzol RNA lysis reagent 5' prime Trypsin Sigma Aldrich
V
Solutions
All solutions are made with ddH2O and sterile filtered before use.
AF-media
76% L-15 medium, 2% 1M HEPES, 2% PS, 20% FBS
BSA 60 mg/ml stock
60 mg BSA, 1 ml PBS
Collagen
1% collagen solution, 3.13 mg/ml, 99% HBS
DEPC water
0.1% DEPC in ddH2O
DMSO for cell culture storage
50% L-15 medium, 2% 1M HEPES, 8% DMSO, 40% FBS
DNase (4 mg/ml)
4 g DNase I, 87.66 mg NaCl, 5.06 mg MgSO4, H2O to 1 ml
Ethanol in DEPC water (75%)
12.5 ml DEPC H2O, Absolute ethanol to 50 ml
EDTA
9.3 EDTA, 50 ml, H2O, pH adjusted to 8.
Fetal Bovine Serum (FBS)
Heat inactivated at 56°C for 45 min.
HEPES
238.3 g HEPES, 1 ml 0.12% phenol red in 1 L ddH2O, pH 7.3
Phenol red
125 g phenol red, 360 µl 1M NaOH, 100 ml H2O
Phosphate Buffered Saline (PBS)
7.07 g NaCl, 0.20 g KCl, 1.94 g NaHPO4*H2O, H2O to 1 L.
Tris-EDTA (TE) Buffer
500 µl Tris-Cl pH8, 10 µl EDTA, H2O to 50 ml.
VI
Tris-acetate-EDTA (TAE) buffer
242 g Tris base, 57.1 ml glacial acetic acid, 100 ml 0.5 M EDTA pH8.
Tris-Cl 1M pH8
121.1 g Tris base, 42 ml HCl, H2O to 1 L.
Trypsin 1%
50 mg trypsin, 50 ml PBS.
VII
B. General cell culture work
B.1. Thawing cells
1.An ampoule was taken from the nitrogen tank and thawed in a water bath (37°C). 
2.The cells were transferred to a centrifuge tube.
3.PBS (5 mL) was added and the tube was centrifuged (1000 rpm, 4 minutes).
4.The supernatant was removed and the pellet was re-suspended in medium (3 ml).
5.The cell suspension was pipetted into a petri dish (100 mm) already containing 5 mL of 
medium (8 ml in total).
6.The petri dish was incubated at 37°C.
7.Passaging cells (100 mm dishes)
8.The media over the cells was removed.
9.The petridish was washed twice with PBS (2 x 10 ml).
10.Trypsin (1 ml, PRODUSENT) was added to the dish, and the cells were incubated 
(37°C) until they had loosened from the dish. This was checked in the microscope.
11.LHC-9 medium (5 ml) was added to the dish and the cell suspension was pipetted to 
a centrifuge tube and centrifuged (1000 rpm, 4 minutes).
12.The supernatant was removed.
13.The pellet was re-suspended in medium. Amount of medium used depended on the 
desired dilution of the cells. 
14.Cell suspension (1 ml) was pipetted to a new petri dish added 7 ml LHC-9 medium (8 
mL in total pr. 100 mm dish).
15.Cells were incubated at 37°C.
B.2.Freezing cells
Same procedure as passaging of cells is followed to point number 5
1.The cell pellet was re-suspended in AF (500 µL) and transferred to a freezing vial. 
2. DMSO freezing solution (8%, 500 µl) was added and the suspension was mixed well.
3.The vial was put in an insulated box and placed at -80°C, 4-6 hours, before placed in 
liquid nitrogen for long term storage. 
VIII
B.3.Collagen coating of petri dishes or cell culture plates
Purified collagen solution for cell culture (0.012 M HCl, 2.7 mg/ml) was diluted in 
HBS to a total concentration of 0.03 mg/ml. Appropriate volume of collagen was added 
to the petridishes or plates, so that it was completely covered. The dishes/plates were 
incubated at room temperature in the LAF bench for 2 hours. The collagen solution was 
removed and the dishes were washed with PBS. 
B.4. Cell culture maintenance
HBEC3-KT cells were maintained in petri dishes (100 mm) until seeded for experi-
ments. The cells were given fresh LHC-9 medium three times a week and passaged 
when reaching ~80% confluence. 
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C.Pre-processing of miRNA 
expression raw data
The RT-qPCR raw data was normalised by using normalisation factors (NF) calcu-
lated in GeNorm (Table B.1). GeNorm use expression quantities to calculate an M-value 
describing the stability of each gene relative to all other genes. The gene with the lowest 
M-value is the most stable (Figure B.1). The NF was calculated by taking the geometric 
mean of the most stably expressed miRNAs. Expression values of raw Cq was stabilised 
by dividing the gene quantity of each sample on the appropriate NF. 
Figure	  B.1:	  Stability	  of	  microRNAs	  across	  all	  samples.	  The	  32	  genes	  with	   lowest	  variance	  (cal-­‐
culated	  in	  Excel)	  was	  imported	  to	  GeNorm.	  In	  addiIon,	  the	  mean	  of	  the	  global	  miRNA	  expres-­‐
sion	   level	   for	  each	  sample	  were	  imported.	  Some	  genes	  occurred	  in	  mulIple	  replicates	  on	   the	  
LDA	  cards.	   	  Stability	   increases	  with	   decreasing	  M,	   indicaIng	  the	  mammalian	  RNU6	  genes	  as	  
the	  most	  stably	  expressed.
X 
Table	  B.1:	   NormalizaIon	  factor	   (NF)	  calculated	  in	  GeNorm	   by	   taking	  
the	   geometric	   mean	   of	   the	   quanIIes	  of	   the	   most	   stably	   expressed	  
microRNAs.
Mouse NF Genotype Sex
LU212 0.9550 Ahr+/+ Female
LU216 1.0010 Ahr+/+ Female
LU227 1.1254 Ahr+/+ Female
LU236 1.0767 Ahr+/+ Male
LU244 0.8893 Ahr+/+ Male
LU255 0.8873 Ahr+/+ Male
LU201 0.9438 Ahr-/- Female
LU211 1.0160 Ahr-/- Female
LU215 0.9840 Ahr-/- Female
LU232 1.1036 Ahr-/- Male
LU234 1.0592 Ahr-/- Male
LU246 0.9919 Ahr-/- Male
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D.Sequence of miRNAs assayed in 
human cell l ine
Expression of seven miRNAs, four from the mouse study in this thesis and three 
selected from the literature, were investigated in immortalised human lung cell lines. Se-
quence of mouse (mmu) and human (hsa) miRNAs and their genomic location is shown in 
Table C.1.
Table	   C.1:	   Sequence	   of	   mouse	   (mmu)	   and	   human	   (hsa)	   miRNAs	   and	   their	   genomic	   locaIons.
miRNA name Sequence Location miRNA 
name
Sequence Location
mmu-miR-27
a
UUCACAGUG
GCUAAGUUC
CGC
Chr. 8
Cluster: 
mir-23a, 
mir-27a, 
mir-24-2, 
mir-3074-2
hsa-miR-27
a
UUCACAGUG
GCUAAGUUC
CGC
Chr. 19
Cluster: 
mir-23a, 
mir-27a, 
mir-24-2mmu-miR-27
a*
AGGGCUUAG
CUGCUUGUG
AGCA
hsa-miR-27
a*
AGGGCUUA
GCUGCUUG
UGAGCA
mmu-miR-33
GUGCAUUGU
AGUUGCAUU
GCA
Chr. 15
Host gene: 
Srebf2
hsa-miR-33
a
GUGCAUUG
UAGUUGCAU
UGCA
Chr. 22
Host gene: 
SREBF2
mmu-miR-33* CAAUGUUUC
CACAGUGCA
UCAC
hsa-miR-33
a*
CAAUGUUUC
CACAGUGCA
UCAC
mmu-miR-33
5-5p
UCAAGAGCA
AUAACGAAA
AAUGU
Chr. 6
Host gene: 
Mest 
hsa-miR-33
5
UCAAGAGCA
AUAACGAAA
AAUGU
Chr. 7
Host gene: 
MEST
mmu-miR-33
5-3p
UUUUUCAUU
AUUGCUCCU
GACC
hsa-miR-33
5*
UUUUUCAUU
AUUGCUCCU
GACC
mmu-miR-59
2
AUUGUGUCA
AUAUGCGAU
GAUGU
Chr. 6
Host gene: 
Grm8
hsa-miR-59
2
UUGUGUCAA
UAUGCGAUG
AUGU
Chr. 7
Host gene: 
GRM8
mmu-miR-59
2*
UCAUCACGU
GGUGACGCA
ACAU
No antisense sequence 
reported
XII
miRNA name Sequence Location miRNA 
name
Sequence Location
mmu-miR-12
2a
UGGAGUGUG
ACAAUGGUG
UUUG
Chr. 8 hsa-miR-12
2a
UGGAGUGU
GACAAUGGU
GUUUG
Chr. 18
Cluster: 
mir-3591
mmu-miR-12
2a*
AAACGCCAU
UAUCACACU
AA
hsa-miR-12
2a*
AACGCCAUU
AUCACACUA
AAUA
mmu-miR-20
3
GUGAAAUGU
UUAGGACCA
CUAG
Chr. 12 hsa-miR-20
3
GUGAAAUGU
UUAGGACCA
CUAG
Chr. 14
Cluster: 
mir-3545
mmu-miR-20
3*
AGUGGUUCU
UGACAGUUC
AACA
No antisense sequence 
reported
mmu-miR-49
4
UGAAACAUA
CACGGGAAA
CCUC
Chr. 12
Cluster: 
mir-379, 
mir-411, 
mir-299, 
mir-380, 
mir-1197, 
mir-323, 
mir-758, 
mir-329, 
mir-494, 
mir-679, 
mir-1193, 
mir-666, 
mir-543, 
mir-495, 
mir-667, 
mir-376c, 
mir-654, 
mir-376b, 
mir-376a, 
mir-300
hsa-miR-49
4
UGAAACAUA
CACGGGAAA
CCUC
Chr. 14
Cluster: 
mir-379, 
mir-411, 
mir-299, 
mir-380, 
mir-1197, 
mir-323, 
mir-758, 
mir-329-1, 
mir-329-2, 
mir-494, 
mir-1193, 
mir-543, 
mir-495
mmu-miR-49
4*
AGGUUGUCC
GUGUUGUCU
UCUC
No antisense sequence 
reported
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E. Genome database search for 
AHRE
A search for AHR response elements (AHRE) in the promoter region of the four 
most differentially expressed microRNAs (miR-592, miR-33*, miR-335-3p, and miR-27a*) 
was performed in mathematica 8 (Wolfram Research) in both mouse and human genome. 
The human genome is implemented in the Mathematica Software, while the mouse ge-
nome (version 37) was downloaded from the National Center for Biotechnology Informa-
tion (NCBI) ftp server (available from ftp.ncbi.nlm.nih.gov) an imported to Mathematica. 
The search was limited to 10 kb upstream and 1 kb downstream of the pre-miRNA se-
quence. These ranges were chosen based on similar type of search previously reported in 
the literature96. Search for both full and core sequence of AHRE-I, and of full AHRE-II was 
performed. miRNA sequences where downloaded from miRBase (http://mirbase.org)
Defining AHRE
ahreI=RegularExpression["[TG][AGCT]GCGTG[AC][GC]A"]; 
ahreII=RegularExpression["CATG[ATGC][ATGC][ATGC][ATGC][ATGC][ATGC]C[TA]TG"];
Defining human pre-miRNA sequence
fullHSAmir27a="CUGAGGAGCAGGGCUUAGCUGCUUGUGAGCAGGGUCCACACCAAG
UCGUGUUCACAGUGGCUAAGUCCGCCCCCCAG"
Search for pre-miRNA sequence in human genome
GenomeLookup[fullHSAmir27a]
Extracting sequence -10 kb to +1 kb of pre-miRNA sequence
mir27aflanking = GenomeData[{{"Chromosome19", -1}, {50003321 - 10000, 50003398 + 
1000}}]
Search for AHRE-I and AHRE-II in -10 kb to +1 kb extracted sequence
StringPosition[mir27aflanking, ahreI]
StringPosition[mir27aflanking, ahreII]
Defining mouse pre-miRNA sequence
Company Name
XIV 
fullMMUmir27a = 
"UGGCCUGAGGAGCAGGGCUUAGCUGCUUGUGAGCAAGGUCCACAGCAAAGUCGU
GUUCACAGUGGCUAGUUCCGCCCCCUGGACCC";
Search for pre-miRNA sequence in mouse genome
StringPosition[mmchr8, StringReplace[fullMMUmir27a, "U" -> "T"]]
Extracting sequence -10 kb to +1 kb of pre-miRNA sequence
mmumiR27aflanking = StringTake[mmchr8[[6]], {11565925 - 10000, 11566011 + 1000}]
Search for AHRE-I and AHRE-II in -10 kb to +1 kb extracted secuense
StringPosition[mmumiR27aflanking, ahreI]
StringPosition[mmumiR27aflanking, ahreII]
Firma
XV
F.Analysis of RNA quality 
The quality of RNA isolated by TRIzol was assayed on a subset of samples by us-
ing Agilent RNA 6000 Nano Kit and Agilent 2100 bioanalyzer (Agilent Technologies). The 
chips contains interconnected microchannels that is used for separation of nucleic acid 
fragments based on their size as they are driven through it electrophoretically. The proce-
dure were performed as described in protocol provided by producer. The quality of the 
samples are given as a RIN value from 1-10 where 10 indicates theoretically completely 
pure and intact RNA. RIN values > 5 is acceptable.
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A
B
G.Poly acrylamide gel 
electrophoresis (PAGE)
Poly acrylamide gel electrophoresis can be used to separate DNA fragments under 
500 nt of length. The method is very specific and can be used to separate DNA mole-
cules varying by only one nucleotide. PAGE was used to analyse PCR products from the 
RT-qPCR of miRNAs. Since the miRNA PCR products are very small a gel concentration 
of 10% was used.
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miR-27a* miR-33a* miR-335* miR-592 RNU6B
Phix
Ladder
Phix
Ladder
H. MetaCore symbols
G protein Adaptor/Regulators
G beta/gamma
Regulators 
(GDI, GAP, GEF, etc.)
Enzymes
Generic enzyme
KINASE PHOSPHATASE
Generic 
  phosphatase
Protein kinase
Generic kinase
Protein 
  phosphatase
Lipid kinase Lipid 
  phosphatase
PHOSPHOLIPASE
Generic phospholipase
PROTEASE GTPase
Generic protease G-alpha
Metalloprotease RAS - superfamily
Channels/Transporters
Generic channel
Ligand-gated 
  ion channel
Voltage-gated 
  ion channel
Transporter
Generic Classes
Receptors
Generic
GPCR
Receptors with 
  kinase activity
Generic binding protein
Compound
Predicted metabolite 
   or user’s structure
Protein
Receptor ligand
Transcription factor
Inorganic ion
RNA
Reaction
DNA
Effects
Positive / activatiion 
Negative / inhibition 
Unspecified 
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